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Abstract
All the new chemical entities/drug molecules intended for therapeutic use must be
administered using an appropriate delivery system/dosage form to achieve maximum
bioavailability. However, designing a drug delivery system is complex as several factors such as
lipophilicity, molecular mass, crystallinity, ionic charge, polymorphic forms and hydrogen
bonding) affect the solubility and permeability of these molecules. Biopharmaceutics drug
classification system (BCS) categorizes the existing drugs into four classes based on the aqueous
solubility and membrane permeability and it is reported that >70% of the drugs are poorly soluble
and belong to BCS class II and BCS class IV. Several physical, chemical and formulation
techniques have been employed to improve the bioavailability. This dissertation delineates several
formulation strategies to improve the solubility and permeability of small molecules for drug
delivery applications.
Global incidence of superficial fungal infections caused by dermatophytes is high and
affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a
broad-spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional
topical formulations of clotrimazole are intended to treat infections by effective penetration of
drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor
penetration, variable drug levels limit the efficiency. The first study was aimed to load clotrimazole
into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were
prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for
size, poly dispersity index (PDI), and entrapment efficiency to obtain optimized formulation.
Optimized formulation was characterized using scanning electron microscopy (SEM), x-ray
diffraction (XRD) and differential scanning calorimetry (DSC). Skin diffusion studies and tape-
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stripping were performed using human skin to determine the amount of clotrimazole accumulated
in different layers of the skin. Results showed that the optimized formulation had vesicle size <250
nm with ~84% entrapment efficiency. XRD and DSC confirmed the entrapment of clotrimazole
into ufosomes. No permeation was observed through the skin up to 24 h following the permeation
studies. Tape-stripping revealed that ufosomes led to accumulation of more clotrimazole in the
skin compared to marketed formulation (Perrigo). Overall, results revealed the capability of
ufosomes in improving the skin bioavailability of clotrimazole.
Perinatal asphyxia caused due to hypoxia complicates and causes hypoxic-ischemic
encephalopathy (HIE). Therapeutic hypothermia widely used to treat HIE and is successful in
50%-60% patient population. It was reported that lutein supplementation showed neuroprotective
properties in rat model of neonatal HIE. Lutein has poor bioavailability owing to poor aqueous
solubility. In the second study, lutein was encapsulated into polymeric nanoparticles (PLGA and
PLGA-PEG-FOLATE) and evaluated enhanced uptake in human neuroblastoma cells. Lutein
loaded polymeric nanoparticles were prepared using O/W emulsion solvent-evaporation
technique. Particle diameter and zeta potential (ZP) were measured using dynamic light scattering
(DLS). Other characterizations included DSC, FTIR, SEM, and in vitro release studies. In vitro
uptake studies were conducted in neuroblastoma cells using flow cytometry, confocal microscopy
and high-performance liquid chromatography analysis. Lutein was successfully encapsulated into
PLGA and PLGA-PEG-FOLATE nanoparticles with uniform size distribution of around 200 nm
and high ZP. Entrapment efficiency of lutein was ~61% and ~73% for lutein PLGA and PLGAPEG-FOLATE nanoparticles, respectively. DSC and FTIR confirmed encapsulation of lutein into
nanoparticles. Cumulative release of lutein was higher in PLGA nanoparticles with 100% release
within 24 hours. In PLGA-PEG-FOLATE nanoparticles, cumulative release was ~80% at
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48 hours. Cellular uptake studies in neuroblastoma cells confirmed a significant increase in lutein
uptake with PLGA-PEG-FOLATE nanoparticles compared to PLGA nanoparticles and lutein
alone. Findings from this study suggest that lutein loaded PLGA-PEG-FOLATE nanoparticles can
be potentially used for treatment of HIE.
Overuse and misuse of antibiotics in clinics and poor new antibiotic pipeline in
pharmaceutical industries have contributed to antibiotic crisis. Silver complexes are effective as
broad-spectrum antibiotics due to chemical nature. Furosemide-silver complex (Ag-FSE) has been
recently reported to have antibacterial activity that is, however, limited by its poor solubility in
water and majority of organic solvents. Solid lipid nanoparticles (SLNs) offer advantages such as
controlled and sustained release, enhanced solubility, scale-up and, biocompatibility. Present study
aims to encapsulate Ag-FSE into SLNs and evaluate its sustained and improved antibacterial
activity. Ag-FSE SLNs were prepared using hot homogenization and ultrasonication method. Size,
PDI and ZP of Ag–FSE SLNs, evaluated using DLS, were 129.8±38.5 nm, 0.114 ± 0.033 and 23.9 ± 3.62 mV, respectively. Ag-FSE SLNs exhibited high encapsulation efficiency (~93%) and
drug loading (~9.3%). Shape of Ag-FSE SLNs was roughly spherical with smooth surfaces.
In vitro release studies confirmed that encapsulation of Ag-FSE into SLNs resulted in sustained
release of Ag-FSE over 96 h. Results also confirmed 2-fold and 4-fold enhancement of activity
against Pseudomonas aeruginosa and Staphylococcus aureus, respectively. In conclusion, Ag-FSE
SLNs can be considered as promising topical antibacterial agent against bacterial infections.
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Chapter 1
Introduction
Development of new chemical entities/drug molecules for clinical use is expensive and
time consuming. After discovery, delivery of these drugs to the site of action is equally challenging
and is influenced by several factors such as absorption and distribution. Drug delivery is defined
as a method/process of administering drugs to achieve desired therapeutic effects. In addition to
the therapeutic effect, balancing the safety to efficacy ratio should also be considered (Tiwari et
al. 2012). Drug delivery to the site of action is achieved by several routes of drug administration
which include oral (by mouth), parenteral (by injection), topical/transdermal (by skin), inhalation
(by nose), and rectal (by rectum). Of these, oral route is the most preferred route of administration
due to safety and ease of administration. However, first pass effect is a drawback, as majority of
the dose administered is eliminated due to the metabolism in the liver. To avoid first pass effect
alternative routes such as parenteral, transdermal and others have been employed but each of them
are associated with their own advantages and disadvantages (Ruiz and Scioli Montoto 2018).
All the drugs intended for therapeutic use have to be administered using an appropriate
delivery system. However, in most cases of therapeutic development, designing of a suitable drug
delivery system is complex. Several challenges are faced by the formulation scientists during the
design and development of an appropriate drug delivery system to improve the bioavailability.
Some of the important factors include physicochemical properties the drug such as lipophilicity
(pKa and LogP), molecular mass, crystallinity, ionic charge, polymorphic forms and hydrogen
bonding which influence the solubility and permeability of new drugs (S. Gupta, Kesarla, and
Omri 2013; Christopher A Lipinski et al. 1997; No Title 2014).
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1.1. SOLUBILITY AND PERMEABILITY
Solubility is a property of a specific solvent-solute combination, defined as the maximum
amount of solute that is dissolved in a given amount of solvent at constant temperature and pressure
(C A Lipinski et al. 2001). It is also defined as the characteristic property of a solute (solid, liquid,
or a gaseous substance) to dissolve in a solvent (solid, liquid, or a gaseous substance) to form a
homogenous solution. Solubility of a solute occurs at a dynamic equilibrium and is expressed as
concentration, molality, mole fraction, mole ratio and other units. LogP (partition coefficient),
which defines the hydrophobicity/hydrophilicity of a compound is a measure of differential
solubility of the compound in octanol (hydrophobic solvent) and water (hydrophilic solvent)
(Savjani, Gajjar, and Savjani 2012). Based on the parts of solvent required for the solute to
dissolve, the United States Pharmacopoeia (USP) and British Pharmacopoeia (BP) has classified
the solubility classed provided in Table 1.1 (Savjani, Gajjar, and Savjani 2012). According to ICH
M9 guideline, a drug molecule is considered highly soluble if the highest dose of the compound is
completely soluble in 250 mL or less of aqueous media over a pH range of 1.2 to 6.8 at 37 ± 1 °C
(ICH 2019).
Table 1.1: Solubility criteria as per USP and BP
S.no

Descriptive term

Part of solvent required per part of solute

1

Very soluble

<1

2

Freely soluble

From 1 - 10

3

Soluble

From 1 - 30

4

Sparingly soluble

From 30 - 100

5

Slightly soluble

From 100 - 1000

6

Very slightly soluble

From 1000 - 10000

7

Practically insoluble

>10000
2

It is already known that all the drugs irrespective of the mode of delivery, should possess
at least limited aqueous solubility for desired pharmacologic activity as water is the major
component of the body (Savjani, Gajjar, and Savjani 2012). In addition, solubility is considered as
one of the critical parameters to achieve required concentration of the drug in systemic circulation
to attain desired pharmacological response. Poor water solubility of drugs often leads to suboptimal outcomes in the patients due to poor bioavailability and variable pharmacokinetics
(Kalhapure et al. 2019). Poor aqueous solubility leads to poor dissolution and limits the
bioavailability of drugs. It would be ideal to synthesize drug candidate with sufficient aqueous
solubility for therapeutic activity (Ishikawa and Hashimoto 2011) however, it is estimated that
nearly 40%-70% of the drugs marketed and 90% of drugs in pipeline are poorly soluble in water
affecting their bioavailability (S. Gupta, Kesarla, and Omri 2013; Kalepu and Nekkanti 2015).
Permeability is defined as the flow of drug across a membrane. Mathematically, it is the
diffusion coefficient of the drug across the membrane times the partition coefficient of the drug
divided by the membrane thickness (Dahan, Miller, and Amidon 2009; Dahan and Miller 2012).
Permeability is an important factor in drug delivery as poor membrane permeability leads to poor
or non-existent efficacy or therapeutic response (Bennion et al. 2017). As solubility and
permeability play a critical role in determining the bioavailability, drugs are classified into 4 main
categories as per biopharmaceutics drug classification system (BCS classification) (ICH 2019).
BCS Classification
The BCS is a scientific framework for classifying a drug molecule based on its aqueous
solubility and membrane permeability (C.-L. Cheng et al. 2004; Ishikawa and Hashimoto 2011).
It is based on the physicochemical and physiological parameters. In the recent years, BCS system
3

is considered as one of the significant prognostic tools developed to facilitate the drug product
development process. It has been adopted by various regulatory/health authority agencies such as
United States Food and Drug Administration (USFDA), European Medicines Agency (EMA) and
World Health Organization (WHO) for drug approvals (Dahan, Miller, and Amidon 2009). All the
marketed drugs have been classified into 4 classes which include (Figure 1.1).
•

Class I: High Solubility and High Permeability

•

Class II: Low Solubility and High Permeability

•

Class III: High Solubility and Low Permeability

•

Class IV: Low Solubility and Low Permeability

Figure 1.1: Biopharmaceutics classification system for drugs.
It is reported in the literature that >70% of the drugs are poorly soluble and belong to BCS
class II and BCS class IV (X. Zhang et al. 2018). Therefore, solubility and permeability
enhancement of poorly soluble/permeable drugs is required to improve the bioavailability of the
drugs. Several techniques have been employed to improve the bioavailability which include
4

(Savjani, Gajjar, and Savjani 2012; X. Zhang et al. 2018; Tiwari et al. 2012; P. K. Bolla et al. 2018;
Goli, Bolla, and Talla 2018).
1. Physical

methods:

Particle

size

reduction

(milling,

micronization

and

nanonization), crystal habit modification such as co-crystallization, and drug
dispersions.
2. Chemical methods: Changes in pH of the solvent, use of buffers and permeation
enhancers, salt formation, derivatization and complexation.
3. Formulation development: Nanoparticles (nanosuspensions, nanoemulsions,
nanocrystals, polymeric nanoparticles and others), micelles, solid dispersions, lipid
based drug delivery systems (self-emulsifying drug delivery systems, solid lipid
nanoparticles (SLNs), liposomes, ufosomes, microemulsions), liquid solid
techniques, and targeted therapy (surface modified drug delivery systems)
4. Miscellaneous methods: Super critical fluid process, use of adjuvants such as
surfactants, solubilizers, cyclodextrins, co-solvents, hydrotrophy and novel
excipients.
Of these, development of an adequate pharmaceutical formulations is considered as a good
strategy to improve the solubility and permeability for existing drug molecules (Kalhapure et al.
2019).

5

Figure 1.2: Formulation strategies to enhance solubility and permeability of drugs.
1.2. OBJECTIVE
The main objective of the dissertation is to develop novel formulations of Clotrimazole (an
anti-fungal agent and a BCS class II drug), Lutein (a neuroprotective agent and BCS class II drug)
and Furosemide Silver (a novel antibiotic and BCS class IV drug) to improve their solubility and
permeability.
1.3. AIMS
1. To prepare and characterize clotrimazole loaded ufosomes for enhanced topical
delivery.
2. To prepare and characterize folate decorated nanoparticles of lutein using PLGAPEG-FOLATE polymer for enhanced uptake via folate receptor mediated
endocytosis.
3. To prepare and characterize furosemide silver loaded solid lipid nanoparticles for
enhanced antibacterial activity.
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Chapter 2: Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development
and In Vitro Studies
Graphical abstract

Illustration 2.1: Clotrimazole loaded ufosomes for topical delivery
Introduction
Global incidence of fungal infections has been on a significant rise since 1980’s affecting
approximately one billion people and are the primary cause of death in one million patients
annually (Bongomin et al. 2017). Majority of fungal infections are opportunistic or secondary
infections in immunocompromised patients with severe diseases such as acquired immune
deficiency syndrome (AIDS), tuberculosis, cancer and chronic obstructive pulmonary disease. The
surge in the incidence fungal infections in the recent times is due to the increased use of surgical
and invasive procedures, immunosuppressants, and antibiotics (AbouSamra et al. 2019). Most
commonly reported fungal infections are superficial in nature affecting skin, hair, nails, and
mucosa however, systemic fungal infections are also reported (M. Gupta, Sharma, and Chauhan
2017; Bongomin et al. 2017). Superficial fungal infections caused by dermatophytes affect around
40 million people in developed and underdeveloped countries and is the fourth most common
cause of infection (M. Gupta, Sharma, and Chauhan 2017; Shivakumar et al. 2012). Common
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fungal pathogens responsible for fungal infections include Candida, Aspergillus, Cryptococcus,
Scedosporium, Zygomycetes and other species (Bongomin et al. 2017; M. Gupta, Sharma, and
Chauhan 2017). Various antifungal agents are used for the treatment of fungal infections which
include azoles (triazoles and imidazoles), allylamines, polyene antibiotics, echinocandins,
griseofulvin and others (AbouSamra et al. 2019; M. Gupta, Sharma, and Chauhan 2017).
Candidiasis, also referred to as yeast infection is the most common fungal superficial
infection caused by the Candida species. Candida albicans is an ubiquitous fungal pathogen
responsible for 50% of the Candida infections and is usually colonized in skin, vagina, mouth and
intestinal tract (AbouSamra et al. 2019; M. A. Alam et al. 2017; Maheshwari et al. 2012). Other
candida pathogens include Candida. krusei, Candida. glabrata, Candida. lusitaniae, Candida.
tropicalis, and Candida. Parapsilosis (Nami et al. 2019). Topical formulations are intended to treat
local infections on the topmost layer of the skin by effectively penetrating the drugs into the
stratum corneum, thus destroying the fungi or the causative organism. Advantages associated with
topical formulations include limited systemic bioavailability of the drug, which reduces the
systemic adverse effects, potential self-medication, increased patient compliance and targeted or
localized therapy. However, topical preparations have disadvantages such as poor dermal or
ungual bioavailability, poor penetration into the stratum corneum, variable drug levels at the site
of infection, greasiness or stickiness of ointments and creams, skin irritation, allergic reactions,
and uncontrolled evaporation of drugs from the preparation (M. Gupta, Sharma, and Chauhan
2017; Bseiso et al. 2015; P. N. Gupta et al. 2005; Juluri et al. 2013; Juluri and Narasimha Murthy
2014). Therefore, there is a need for novel topical formulations to address the problems associated
with the current existing formulations. Recently, formulation scientists have explored
nanoparticle-based drug delivery systems to improve topical formulations. This is done by
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delivering active drugs precisely to the infection site while enhancing skin penetration, reducing
irritation and increasing the sustained effect (Pople and Singh 2011). Several novel drug delivery
systems have been formulated to encapsulate antifungal agents and improve their efficacy. Some
of them include microemulsions, nanoemulsions, niosomes, dendrimers, solid lipid nanoparticles,
liposomes, ethosomes, lipid nanoparticles and polymeric nanoparticles (M. Gupta, Sharma, and
Chauhan 2017).
Clotrimazole, a broad spectrum less toxic imidazole antifungal agent is widely used to treat
Candidiasis. It acts by inhibiting cytochrome 14α-demethylase enzyme of the fungal cells
responsible for cell wall synthesis (Santos et al. 2013). Chemically, clotrimazole is 1-((2chlorophenyl) diphenylmethyl)-1H-imidazole, insoluble in water (0.49 mg/L) with Log P of 6.1
and pKa 6.7 (Waugh and Medical 2007; Ravani et al. 2013; M. Gupta, Sharma, and Chauhan
2017). It is the first oral azole approved for fungal infections; however, it is not used as an oral
agent due to its limited oral absorption and systemic toxicity. Currently, clotrimazole is available
as conventional topical formulations such as cream (Lotrimin AF and Gyne-Lotrimin), solution
(Lotrimin AF) and lotion (Lotrimin AF) (M. Gupta, Sharma, and Chauhan 2017). Topical
bioavailability of clotrimazole is very low ranging from 0.5%-10% due to its poor aqueous
solubility (D. Waugh 2011). Therefore, clotrimazole must be loaded into a suitable drug delivery
system to enhance its topical bioavailability at the infection site. It is reported in the literature that
clotrimazole has been loaded into various novel drug delivery systems such as nanogels,
microemulsions, solid lipid nanoparticles, nano-capsules, ethosomes, three-dimensionally
structured hybrid vesicles, and liposomes (Santos et al. 2013; Esposito et al. 2013; Maheshwari et
al. 2012; M. A. Alam et al. 2017; Manca et al. 2019). On the other hand, vesicular drug delivery
systems have become more popular in recent times due to their advantages such as prolonged drug
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release, improved drug penetration, targeted delivery to the site of infection, and improved
physical stability. Very recently, Csongradi et al, reported the use of ufosomes as a potential topical
drug delivery vehicle. They loaded roxithromycin, a poorly water-soluble antibiotic into ufosomes
and evaluated its release and skin distribution. Results showed that significant amount of
roxithromycin accumulation in the epidermis-dermis layer of the skin with no permeation across
the skin layers (Csongradi et al. 2017). Ufosomes are lipid based vesicular drug delivery systems
otherwise called unsaturated fatty acid liposomes. They are colloidal suspensions of fatty acids
and ionized soaps which can form lipid bilayers and entrap active lipophilic drugs. Loading of
clotrimazole into ufosomes can result in enhanced skin penetration due to the lipophilic nature of
the vesicles. Ufosomes being fatty acid vesicles, could interact with the stratum corneum and
enhance the topical bioavailability of clotrimazole (Csongradi et al. 2017; Patel, Patel, and Jani
2011). Moreover, preparation ufosomes is economical as the fatty acids are inexpensive compared
to other lipids (Patel, Patel, and Jani 2011). Therefore, the present study aims to prepare and
characterize clotrimazole loaded ufosomes using cholesterol and sodium oleate. Clotrimazole
ufosomes were prepared by thin film hydration technique. Effect of drug to excipient ratio on size
and entrapment efficiency was studied to optimize the formulation. Further, formulation was
characterized, and skin diffusion studies were performed using human skin to determine the
amount of clotrimazole accumulated in different layers of the skin.
Materials and Methods
Materials
Clotrimazole and cholesterol were purchased from Alfa Aesar (Ward Hill, MA, USA).
Sodium oleate was purchased from TCI America (Portland, OR, USA). Methanol (ACS grade),
methanol (HPLC grade), PBS (pH 7.4) and chloroform were procured from Fisher Chemicals
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(Fair Lawn, NJ, USA). Hydroxy propyl methyl cellulose (HPMC) (MW: 86,000, viscosity
4,000 cP at 2% solution) was obtained from Acros Organics (Fair Lawn, NJ, USA). Cadaver skin
for permeation and skin diffusion studies was obtained from Zen-Bio Inc., (Research Triangle
Park, NC, USA). Marketed Clotrimazole 1% cream (Perrigo) was purchased from local pharmacy
store in El Paso, TX, USA. Deionized water (resistivity of 18.2 MΩ) used for all experiments was
obtained from in-house Milli-Q® IQ 7000 Ultrapure Water System (EMD Millipore, Bedford, MA,
USA).
Methods
Preparation of ufosomes
Clotrimazole loaded ufosomes were prepared using thin film hydration method reported in
the literature with slight modifications (Patel, Patel, and Jani 2011; Verma et al. 2014; Csongradi
et al. 2017). Briefly, all the components of the vesicles (clotrimazole, sodium oleate and
cholesterol) were dissolved in 10 mL of chloroform-methanol solution (1:2). Clear solution
obtained was transferred to a beaker and kept on a magnetic stirrer for complete evaporation of the
solvents until a thin film was formed. The thin film was then hydrated with 5 mL of PBS (pH 7.4)
for 2 h. The formed vesicular dispersion was sonicated for 5 minutes to obtain ufosomes with
uniform sizes. Optimization of the formulation was performed by screening six different ratios of
clotrimazole, sodium oleate and cholesterol for vesicle size and entrapment efficiency. Ufosomal
gels for permeation studies were prepared by adding 100 mg (2% w/v) and 50 mg (1% w/v) of
HPMC to the optimized vesicular dispersion.
Determination of vesicle size, polydispersity index (PDI) and zeta potential (ZP)
Dynamic light scattering (DLS) technique applying photon correlation spectroscopy was
used to measure vesicle size and PDI. Zeta potential was determined by measuring the
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electrophoretic mobility. Ufosomal dispersion samples (100 µL) were diluted in 10 mL double
distilled de-ionized water and measurements were obtained using Malvern Zetasizer (Nano ZS90,
Malvern, Worcestershire, UK) at 25 °C. All the experiments were performed in triplicate.
Clotrimazole quantification by HPLC
The concentrations of clotrimazole in all the samples obtained during the analysis was
determined using Waters Alliance e2695 HPLC with 2998 photodiode array detector and
Empower 3.0 software. Clotrimazole separation was carried out on a reverse phase-C18 column
(Phenomenex®; 250 mm × 4.6 mm; 5 µm particle size) at 25 °C under isocratic conditions. Mobile
phase was methanol-water (90:10 v/v) at a flowrate of 1 mL/min. A sample of 20 µL was injected
and the analyte was monitored at 229 nm for 10 minutes. Retention time of clotrimazole was
5.5 minutes. All standard samples were prepared with methanol and filtered through 0.45 µm filter
before injection (Santos et al. 2013).
Determination of entrapment efficiency
Entrapment efficiency of the formulations was determined using ultra-centrifugation
method (Salama and Aburahma 2016). In brief, the vesicular dispersions were transferred to tubes
and centrifuged at 15,000 rpm for 4h at 4 °C (Beckman Ultracentrifuge). The supernatant was
discarded to remove the unentrapped drug in the formulation. The lipid precipitate obtained was
then mixed with methanol, bath sonicated for 30 minutes and kept overnight in shaking water bath
(25 °C; 100 rpm) for complete extraction of entrapped clotrimazole. The resultant solution was
centrifuged at 15,000 rpm for 30 minutes at 4 °C to separate methanol and lipid layer, if any. After
centrifugation, supernatant was diluted appropriately and the concentration of entrapped
clotrimazole was determined using HPLC. Entrapment efficiency was calculated using the
following formula.
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Entrapment efficiency (%EE) = (Amount of clotrimazole remained in vesicles)/(Initial
amount of clotrimazole) × 100
Surface morphology
Quanta 600F scanning electron microscope with a high-resolution field emission source
(ThermoFisher Scientific, Hillsboro, OR) was used to study surface morphology of ufosomes.
Prior to imaging, samples were dispersed in methanol and the mixture was drop casted onto a piece
of silicon wafer (5 mm × 5 mm) and fixed with double sided conductive tape. Further, samples
were air dried and coated with gold using a gold sputter [Gatan 682 Precision Etching and Coating
System (PECS) (Gatan, Inc., Pleasanton, CA)]. High resolution images of the ufosomes were
visualized under high vacuum at an accelerated voltage of 20 keV.
X-ray diffraction (XRD) analysis
XRD analysis was carried out using Rigaku Miniflex X-Ray Diffractometer (Rigaku
Corporation, Tokyo, Japan). A double-sided adhesive tape was applied over the sample holder and
powdered (lyophilized) samples were poured onto the sample holder using a thin spatula. Intensity
of diffracted beam was analyzed in 2θ range between 10° and 70°. All samples were analyzed
using JADE software.
Differential Scanning Calorimetry (DSC)
DSC analysis was performed for lyophilized ufosomes, clotrimazole, sodium oleate and
cholesterol using DSC822e (Mettler Toledo) instrument. Samples (5-10 mg) were weighed in
40 µL aluminum pans and hermetically sealed using a crimping device. An empty aluminum pan
was used as a reference standard on the other side. Nitrogen was used as purge gas during the
analysis at a flow rate of 20 mL/min. Samples were held at 0 °C isotherm for 5 minutes then heated
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at 10 °C/minutes to 260 °C (from 0 °C - 260 °C, 260 °C - 0 °C, 0 °C - 260 °C and finally 260 °C
– 0 °C). All the thermograms were recorded and analyzed using STARe software.
In vitro permeation studies
Preparation of skin
Skin penetration studies were performed using a human cadaver defatted skin from the
abdominal region of a Caucasian male (ZenBio Inc., Lot#SKIN122117C). Skin acquired from the
skin bank was stored in -20 °C freezer until needed. For permeation studies, the skin samples were
thawed at 4 °C for 24 hours. On the day of permeation study, the skin samples were removed from
the 4 °C and allowed to equilibrate at room temperature for 15 minutes. After equilibration, skin
was shaved to remove any hair. Further, the skin was rehydrated in 150 mL of PBS (pH 7.4) for
30 minutes at room temperature (Barbero and Frasch 2016; Pere et al. 2018). Immediately after
rehydration, the full thickness skin was appropriately cut to size of the PermeGear® in-line cells,
1.77 cm2, and mounted between the donor and receptor compartments for skin diffusion studies
(Hopf et al. 2014).
Automated flow through diffusion cells
In vitro permeation studies were performed using PermeGear® ILC-07 automated system
(PermeGear, Riegelsville, PA) incorporated with seven in-line flow-through diffusion cells, made
of Kel-F. Diffusion cells contain a donor and receptor chambers clamped using threaded rods with
adjustable locking nuts. Inlet and outlet ports of the receptor chamber (254 µL receptor chamber
volume) were connected to the Tygon tubings having 1/ 4-28 HPLC fittings and all cells were
placed in cell warmer connected to a Julabo BC4 circulating water bath (Seelbach, Germany) to
maintain the temperature at 37 °C. All the cells were connected to a multi-channel peristaltic
pump® IPC (Ismatec, Zurich, Switzerland) which draws receptor solution from a reservoir
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(Figure 2.1). The diameter of the diffusional area was 1 cm (total diffusional area: 0.785 cm2). Full
thickness skin (epidermis facing donor compartment) was mounted in the cells between the donor
and receptor chambers and clamped using the adjustable locking nuts. Formulations were placed
in the donor chamber and the receptor fluid (PBS pH 7.4) was pumped at a flow rate of 4 mL/h
through each cell. Receptor fluid was collected in the receptor vials of 20 mL capacity at predetermined time intervals up to 24 h (K. P. Bolla et al. 2020; De Leon et al. 2016; Córdoba-Díaz
et al. 2000). The amount of clotrimazole permeated through the skin was determined by analyzing
the samples using HPLC method described in the earlier sections.

Figure 2.1: Automated flow through cells
Tape stripping
Tape stripping method reported in the literature was employed to determine the amount of
clotrimazole accumulated in stratum corneum-epidermis and epidermis-dermis layers of the skin.
After completion of skin permeation studies, the skin samples mounted were carefully removed
from the cells and placed on a flat surface to view the diffusion area. The excess formulations on
the skin surface was removed by gently dabbing the skin using soft tissue. Stratum corneum and
some parts of epidermis layers was separated using 3M Scotch® Magic tape™. Pre-cut tapes were
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pressed onto the skin with the thumb and removed immediately using forceps to remove stratumcorneum (first strip was discarded). An average of 10 strips were required to remove the stratum
corneum completely. The remaining epidermis-dermis layers of the skin was cut into tiny pieces
using clean surgical scissors. All the strips (except the first one) and skin pieces were transferred
to a conical tube with 10 mL methanol and clotrimazole was extracted by sonicating in an
ultrasonic water bath for 30 mins and left to stand overnight at 4 °C. After extraction, the resulting
solution was centrifuged for 30 mins at 15,000 rpm and the drug content in the supernatant was
analyzed using HPLC (Kahraman et al. 2018; Binder et al. 2018; Csongradi et al. 2017; Dwivedi
et al. 2016).
Statistical analysis
Statistical analysis was performed using GraphPad Prism® software (version 5.0, San
Diego, CA). Data are expressed as mean ± SD for DLS and entrapment efficiency results and mean
± SEM for skin diffusion results. One-way ANOVA followed by followed by Bonferroni’s posttest
was applied to determine statistical significance. A p-value of < 0.05 was considered as statistically
significant.
Results and Discussion
Optimization of clotrimazole loaded ufosomes
Optimization studies were aimed to obtain smaller sized ufosomes with high entrapment
efficiency. For this, different ratios of clotrimazole, cholesterol and sodium oleate were screened
for vesicle size and entrapment efficiency. As most of the clotrimazole topical formulations
available commercially are of 1%, the concentration of clotrimazole in all the formulations was
constant at 1% w/v in all the formulations. The ratio of non-ionized fatty acids and ionized fatty
acids determines the stability of ufosomes (Patel, Patel, and Jani 2011). Therefore, effect of six
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different ratios of cholesterol and sodium oleate on vesicle size, PDI, ZP and entrapment efficiency
were studied to obtain the optimized formulation. Cholesterol (neutral fatty acid) and sodium
oleate (ionized fatty acid) were selected for formulation of ufosomes as they are widely used in
lipid based topical formulations. Moreover, they are approved by USFDA as inactive ingredients
(USFDA n.d.). Cholesterol, a naturally available unsaturated steroid is capable of forming
phospholipid bilayers which entrap hydrophobic drugs. In addition, cholesterol enhanced the
stability and permeability of the vesicles (“10 Final Report on the Safety Assessment of
Cholesterol” 1986; Doppalapudi et al. 2017). It has been used in the preparation of various
formulations which include liposomes, ufosomes, topical ointments and creams, transfersomes,
niosomes, secosomes, and solid lipid nanoparticles (Kavian et al. 2019; Csongradi et al. 2017; Md
et al. 2017; Roberts et al. 2017; Meng et al. 2019; Kravchenko et al. 2011). Sodium oleate is a salt
of unsaturated fatty acid (oleic acid) and used as a permeation enhancer in topical formulations
and is GRAS chemical (Csongradi et al. 2017; Witteveen 2018; Oliveira et al. 2015). As ufosomes
are formed in narrow pH range of 7-9, phosphate buffered saline (PBS) 7.4 was used for hydration.
Any differences in the pH of hydration medium will lead to the formation of oil droplets or
precipitates (pH <7) or soluble micelles (pH >9) in the formulation (Salama and Aburahma 2016).
Determination of size, PDI and ZP
Table 2.1., summarizes the size, PDI and ZP of ufosomes prepared using different ratios of
cholesterol, sodium oleate and clotrimazole. Results showed that increase in the concentration of
sodium oleate and cholesterol led to the formation of ufosomes with smaller vesicle sizes.
Ufosomes with particle sizes <300 nm was obtained with Ufo_6 (1:2:2 ratio) [clotrimazole (50
mg), sodium oleate (100 mg) and cholesterol (100 mg)]. However, all the formulations were
polydisperse in nature with PDI ranging from 0.4 to 0.7. Size distribution analysis of all the
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formulations is provided in Table 2.2. Ufo_6 formulation showed trimodal size distribution
indicating the presence of vesicles with different sizes. Analysis of size distribution curves showed
that the vesicle size was <200 nm for majority of the vesicles (Figure 2.2). Decrease in the vesicle
size with increase in cholesterol could be attributed to higher packing densities and stability of
vesicles with increased cholesterol concentration (Kravchenko et al. 2011). Similar findings were
obtained when diclofenac was loaded into cholesterol vesicles (diclosomes) (Tavano, Mazzotta,
and Muzzalupo 2018). As reported in the literature, ZP values for all the ufosomes was high
ranging from -73.7 mV to -101 mV indicating high stability. Increase in the sodium oleate (ionized
soap of fatty acid) concentration resulted in the shift of ZP to higher negative values.
Table 2.1: Summary of vesicle diameter, PDI and ZP results of ufosomes. Data are presented as
mean ± SD (n=3)
Clotrimazole:Choles

Vesicle

terol:Sodium Oleate

diameter (nm)

Ufo_1

1:0.5:1

Ufo_2

Formulation

PDI

ZP (mV)

1177 ± 156

0.414 ± 0.164

-74 ± 3

1:1:0.5

848 ± 239

0.638 ± 0.166

-74 ± 3

Ufo_3

1:1:1

432 ± 140

0.583 ± 0.069

-74 ± 5

Ufo_4

1:2:1

374 ± 67

0.589 ± 0.064

-75 ± 7

Ufo_5

1:1:2

752 ± 179

0.702 ± 0.067

-101 ± 5

Ufo_6

1:2:2

234 ± 59

0.581 ± 0.132

-98 ± 3

Table 2.2: Summary of size distribution analysis of ufosomes
Formulation

Vesicle diameter (nm)

Size distribution

Intensity (%)

(nm) (mean ± SD)
Ufo_1

1282

1207 ± 342

18

93.7

Ufo_2

Ufo_3

Ufo_4

Ufo_5

Ufo_6

894

493

367

720

207

128 ± 27

5.2

5560

1.1

947 ± 191

82.7

96 ± 17

17.3

396 ± 80

72.5

68 ± 12

27.5

546 ± 140

65

86 ± 21

35

808 ± 167

59.6

123 ± 28

40.4

144 ± 50

71.6

782 ± 194

19.4

42 ± 9
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Figure 2.2: Size distribution curve of Ufo_6
Determination of Entrapment Efficiency
Overall, all formulations exhibited high clotrimazole entrapment with entrapment
efficiency ranging from ~76% to ~87% indicating ufosomes as ideal carrier for entrapment of
lipophilic drugs. Ufosomes contain fatty acids which are oriented in the form of a bilayer with
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hydrophobic tails towards the interior resulting in greater entrapment of drugs (Patel, Patel, and
Jani 2011). Ufo_6 formulation had high entrapment efficiency of ~99% for one sample among the
triplicates analyzed (high standard deviation). Although, there was no significant difference
between the formulations, a trend of greater entrapment was observed with increase in the drug
lipid ratio. This could be attributed to higher rigidity of the ufosomal membrane leading to greater
drug retention (Doppalapudi et al. 2017). Also, high entrapment efficiency at lower drug to lipid
ratio could be attributed to the presence of the enough lipid for entrapment of clotrimazole (Das,
Ng, and Tan 2012).
Based on the DLS and entrapment efficiency results, Ufo_6 formulation was chosen as the

Encapsulation Efficiency (%)

optimized formulation for further studies due to small vesicle size and high entrapment efficiency.

100
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Ufosome Formulation

Figure 2.3: Summary of entrapment efficiency results of ufosomes. Data are presented as mean ±
SD (n=3)
Surface morphology
Scanning electron microscopy (SEM) is one of the most widely used techniques to study
the surface morphology of nano and microparticles. This technique uses electron beam as a probe
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to acquire high resolution images of the particles whereas, DLS provide the hydrodynamic radius
of the particles. SEM images of the ufosomes are provided in Figure 2.4. The images revealed that
the ufosomes were roughly spherical with smooth surfaces. Vesicle size observed with SEM was
larger compared to the sizes obtained from DLS. The difference in the sizes could be attributed to
loss of water during the air-drying process resulting in collapse and fusion of vesicles.

(a)
(b)
Figure 2.4. SEM images of clotrimazole loaded ufosomes (Ufo_6).
XRD analysis
XRD studies were performed to study the polymorphic changes of compounds used in the
formulation of ufosomes. Crystalline nature of the compounds affects important properties such
as stability, solubility, and bioavailability. Amorphous forms of drug molecules are characterized
with higher solubilities and increased bioavailability (P. K. Bolla et al. 2019; Renukuntla 2018a).
XRD diffractograms for clotrimazole, cholesterol, sodium oleate and clotrimazole loaded
ufosomes are provided in Figure 2.5. Results showed characteristic peaks at 10.8°, 13.2° (high
intensity), 19.4°, 20.3°, 21.5°, 24.0°, 25.3°, and 26.2° confirming the crystalline nature of
clotrimazole (Figure 2.5D). In addition, characteristic peaks were recorded for cholesterol (15.3°,
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15.8°, and 30°) (Figure 2.5A) and sodium oleate (30.3°) (Figure 2.5C). However, XRD results of
clotrimazole loaded ufosomes showed the absence of characteristic peaks of clotrimazole (Figure
2.5B). This confirms the entrapment of clotrimazole into ufosomes and transition of clotrimazole
from crystalline to amorphous forms. Similar results were observed in other reports studying the
entrapment of drug molecules into lipid-based drug delivery systems (Jaiswal et al. 2014; Bose
and Michniak-Kohn 2013; AbouSamra et al. 2019; Das, Ng, and Tan 2012).

Figure 2.5: XRD diffractograms of (A) cholesterol, (B) clotrimazole loaded ufosomes, (C)
sodium oleate and (D) clotrimazole.
DSC
DSC is a widely used technique to understand the melting and recrystallization behavior
of drug molecules. It is a thermo-analytical technique, that determines the thermodynamic
properties of materials by providing information about the polymorphic changes when subjected
to a controlled heat flux (Ribeiro et al. 2016; Rodriguez et al. 2019). Thermal behavior of
clotrimazole, cholesterol, sodium oleate and clotrimazole loaded ufosomes is provided in
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Figure 2.6. DSC thermogram of clotrimazole showed a characteristic endothermic peak at
143.98 °C. In addition, cholesterol had a melting point of 147.63 °C. No specific thermal behavior
was observed for sodium oleate and clotrimazole loaded ufosomes. Disappearance of characteristic
endothermic peak of clotrimazole in lyophilized ufosomes confirm the entrapment and
transformation from crystalline to amorphous form. DSC thermograms also confirm the internal
arrangement drug in vesicles (Buchiraju et al. 2013). Clotrimazole is entrapped in cholesterol
bilayer and carboxylic groups of sodium oleate are on the surface of vesicles. Overall, DSC results
complemented the XRD results.

Figure 2.6: DSC Thermograms of (A) sodium oleate, (B) clotrimazole, (C) cholesterol and (D)
clotrimazole loaded ufosomes. Sharp endothermic peaks in thermograms (B) and
(C) indicates the melting points of clotrimazole and cholesterol at 147.63 °C and
143.98 °C, respectively. No peak related to drug was found in clotrimazole loaded
ufosomes (D).
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In vitro permeation studies
Skin diffusion studies
In formulation research and development, in vitro permeation studies are conducted to
predict skin permeation of topical and transdermal formulations (Ruela et al. 2013; Azarmi, Roa,
and Lobenberg 2007). Flow-through cells were used for continuous flow of receptor fluid to
maintain sink conditions. Moreover, this type of system is more suitable to simulate in vivo
conditions and preferred for several drug molecules (Cordoba-Diaz et al. 2000). For our
experiments, 24-h permeation studies were conducted on human skin for ufosome suspension and
ufosomes in HPMC gels (1% and 2%) with blanks as negative control. Permeation studies were
also performed using a dialysis membrane to confirm the release of clotrimazole from the
formulations. For comparison, permeation studies were also conducted for marketed Clotrimazole
1% cream (Perrigo) composed of benzyl alcohol, cetostearyl alcohol, cetyl esters wax,
octyldodecanol, polysorbate 60, and sorbitan monostearate. Sampling intervals were 1, 2, 3, 4, 5,
6, 7, 8, 12, 16, 20, and 24 h. Results showed that clotrimazole was not permeated through the skin
up to 24 h following the permeation studies from all the tested formulations. Similar results were
observed in reports published in literature with clotrimazole microemulsions (Kaewbanjong et al.
2018), clotrimazole loaded three-dimensionally-structured hybrid vesicles (Manca et al. 2019) and
roxithromycin ufosomes (Csongradi et al. 2017). As most of the fungal infections are localized on
the surface of the skin, systemic bioavailability of clotrimazole is not required. Therefore,
ufosomes could be a potential carrier for topical delivery of clotrimazole.
Skin retention study (Tape-stripping)
Tape-stripping experiments were performed to determine the penetration of clotrimazole
into stratum-corneum, epidermis and dermis of the skin. Results showed that clotrimazole
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accumulation in stratum corneum-epidermis and epidermis-dermis layers was significantly higher
with ufosomes suspension compared to ufosomes gel and marketed cream (p < 0.05). Ufosome
gels showed higher levels of clotrimazole in the skin, however, they were not significantly higher
compared to the marketed cream (p > 0.05). These findings were consistent with other studies
where entrapment of drugs into lipid vesicles enhanced the topical bioavailability of drugs.
Enhancement of topical bioavailability could be attributed to simultaneous mechanisms such as:
i) increased solubility due to transformation of clotrimazole from crystalline to amorphous form,
ii) penetration enhancing property of cholesterol and sodium oleate, and iii) high interaction of
lipids could modify the structure of stratum corneum and iv) enhanced thermodynamic activity
(Csongradi et al. 2017; Dwivedi et al. 2016). The amount of clotrimazole accumulated in stratum
corneum-epidermis and epidermis-dermis layers is provided in Figure 2.7 and Figure 2.8,
respectively. Compared with marketed formulation, there was ~16-times, ~2.3-times, ~1.5-times
enhanced penetration of clotrimazole into stratum corneum with ufosomes suspension, ufosome
1% gel and ufosomes 2% gel, respectively (Figure 2.7). Whereas, the amount of clotrimazole
accumulated in the epidermis-dermis layer was ~6-fold, ~3.3-fold, and ~3.2-fold higher with
ufosomes suspension, ufosome 1% gel and ufosomes 2% gel, compared to marketed formulation
(Figure 2.8). Overall, topical diffusion studies revealed enhanced penetration and targeted delivery
of clotrimazole only to the superior layers of the skin. This proves that ufosomes could be effective
in enhancing the required drug concentrations at the target cutaneous tissues.
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Figure 2.7: Amount of clotrimazole accumulated in stratum corneum-epidermis layers of skin.
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Figure 2.8: Amount of clotrimazole accumulated in epidermis-dermis layers of skin. Data are
represented as mean ± SEM (n=3)
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Conclusions
Entrapment of hydrophobic drugs into lipid-based vesicles can improve the topical
bioavailability. In the present study, clotrimazole loaded ufosomes were successfully prepared
using cholesterol and sodium oleate. Optimized formulation with vesicle size <250 nm and high
entrapment efficiency was obtained with 1:2:2 ratio of clotrimazole (50 mg), cholesterol (100 mg)
and sodium oleate (100 mg). DSC and XRD results confirmed the successful entrapment of
clotrimazole into ufosomes. Spherical morphology of ufosomes was confirmed by SEM. In vitro
permeation studies using human skin revealed that clotrimazole did not permeate through the skin.
Topical diffusion studies (tape-stripping) confirmed that ufosomes suspension significantly
increased the accumulation of highly lipophilic drug (clotrimazole) into the viable epidermis and
dermis as compared to the ufosomes gels and commercially available cream. Thus, this study
proves that ufosomes could be a potential carrier to enhance the topical bioavailability and targeted
delivery of drugs. However, the results from this study are preliminary and should be further
confirmed with in-depth formulation development, stability, and pre-clinical studies before clinical
applications.
Future studies
In this dissertation project, I have successfully prepared and characterized novel ufosomes
based formulation for enhancing the topical bioavailability of clotrimazole using several in vitro
techniques. For extending this project, the future studies include: (1) Evaluation of in vitro
antifungal activity of clotrimazole loaded ufosomes on different strains of Candida albicans and
to evaluate the in vivo antifungal activity to compare with marketed formulation. (2) Further,
in vivo pharmacokinetics and biodistribution of clotrimazole after topical application will be
studied.
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Chapter 3: Preparation and Characterization of Lutein Loaded Folate Conjugated
Polymeric Nanoparticles
Graphical abstract

Illustration 3.1: Proposed mechanism of lutein loaded PLGA-PEG-FOLATE nanoparticles for
treatment of neonatal HIE.
Introduction
Perinatal asphyxia (PA) caused due to a reduced oxygen supply to the brain at the time of
birth is the main cause of mortality in one million neonates per year globally. Other causes for PA
include various intricate perinatal events such as maternal/fetal hemorrhage, umbilical cord
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compression, and uterine rupture leading to oxygen deprivation (Fattuoni et al. 2015). While the
majority of neonates with PA recover from their episodes, in few cases, the condition complicates
and causes hypoxic-ischemic brain injury, which subsequently leads to hypoxic-ischemic
encephalopathy (HIE) (SE et al. 2011). Neonatal HIE affects approximately 0.1% to 0.3% of live
births in developed nations and 2.6% in under-developed nations (Joseph et al. 2018). Globally,
HIE is the main cause of mortality in about 23% of neonatal deaths. It is estimated that about,
15%-20% of the neonates with HIE die in the neonatal period and around 25% of the survivors
develop severe neurological morbidities (SE et al. 2011; Joseph et al. 2018; Vannucci and Perlman
1997; Shankaran et al. 2005). Neurological/psychological morbidities associated with HIE include
cerebral palsy, seizures, blindness, learning disabilities, cognitive delays, motor and intellectual
disabilities (Vannucci and Perlman 1997; Fattuoni et al. 2015). Several biochemical mechanisms
such as inflammation, excitotoxicity, and oxidative stress are involved in the pathophysiology of
HIE, which ultimately leads to neuronal cell death (Foster et al. 2017; Busl and Greer 2010). In
clinical settings, the most widely used treatment for HIE is therapeutic hypothermia, with a success
rate of only 50%-60% (Joseph et al. 2018). Other classes of drugs used in the past include
glucocorticoids, diuretics, and barbiturates for cerebral edema related to HIE (Vannucci and
Perlman 1997). In recent times, there have been attempts to explore the use of various agents such
as neuroprotective agents, anti-inflammatory agents, free-radical scavengers, and oxygen free
radical generation inhibitors as an adjuvant therapy to hypothermia in clinical settings (Joseph et
al. 2018; Vannucci and Perlman 1997). Efficacy of agents such as curcumin, melatonin, xenon,
allopurinol, and erythropoietin, a brain-derived neurotrophic factor in preclinical models of HIE
has been proven (Joseph et al. 2018; Y. Cheng et al. 1997; Martinello et al. 2017). However, none
of these agents were effective in reducing the severity of HIE in clinical settings. Therefore, novel
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strategies with new treatments are required to ameliorate the severity of HIE and reduce mortality
and morbidity (Vannucci and Perlman 1997; Martinello et al. 2017).
One such promising therapeutic agent is Lutein. In 2017, Foster et al. evaluated the role of
lutein as a neuroprotective agent in a rat model of neonatal hypoxic-ischemic brain injury. Results
from this study had proven that there was significant reduction of histological brain injury scores,
inflammatory mediators, and hypoxia-inducible proteins such as HIF-1α with lutein treatment.
Also, lutein supplementation to rats resulted in the selective accumulation of lutein in neonatal rat
brains through breast milk (Foster et al. 2017; Gong et al. 2017). Lutein is a dihydroxy xanthophyll
carotenoid and is available abundantly from green leafy vegetables, fruits, flowers, and egg yolk
etc. (Hu et al. 2012; Li et al. 2009). As animals/humans cannot synthesize lutein, it must be
obtained from diet. The neuroprotective effects of Lutein are attributed to its anti-inflammatory
and antioxidant properties (Li et al. 2009; Lim et al. 2016; do Prado Silva et al. 2017).
Unfortunately, lutein has poor bioavailability due to high lipophilicity (Log P 7.9) and poor
aqueous solubility (Ozawa et al. 2012; “Lutein” n.d.). Therefore, there is an unmet need for
developing a new formulation of lutein with enhanced bioavailability.
The approach of utilizing polymeric nanoparticles to enhance bioavailability of drugs with
poor biopharmaceutical properties has been proven effective (Joseph et al. 2018; El-Say and ElSawy 2017). Furthermore, polymeric nanoparticles have advantages including biocompatibility,
enhanced stability, sustained release, and improved efficacy (El-Say and El-Sawy 2017; Crucho
and Barros 2017; Kumari, Yadav, and Yadav 2010; Khan, Saeed, and Khan 2017; Bahrami et al.
2017). Another advantage of polymeric nanoparticles is the possibility of covalent conjugation
with ligands enabling targeted drug delivery to tissues of interest (Masood 2016). Polymeric
nanoparticles are prepared using biodegradable polymers such as poly (lactide co-glycolide)
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(PLGA), gelatin, chitosan, albumin, alginate, polycaprolactone, polyglycolides, poly (methyl
methacrylate), and polyethylene glycol (PEG) (Banik, Fattahi, and Brown 2016; El-Say and ElSawy 2017). Folate receptors are expressed in the brain and blood brain barrier and can be utilized
for active targeting of drugs for neurological disorders such as HIE and brain cancer. As we know,
neuronal cells after terminal maturation cannot be propagated in vitro, so lutein uptake studies
were carried out in neuroblastoma cells as a model for brain cells. Neuroblastoma cell lines have
been extensively used to study various neuronal properties including drug uptake studies. It has
been reported that drugs such as doxorubicin, etoposide, docetaxel have been encapsulated in
folate decorated NP formulations for brain tumors (Guo et al. 2017). Therefore, it is hypothesized
that folate conjugated PEG-PLGA nanoparticles (PLGA-PEG-FOLATE) may increase the lutein
uptake by brain cells through via receptor mediated endocytosis (Illustration 3.1) (Antony 1996;
C. Alam et al. 2017; Zhao et al. 2011; Guo et al. 2017). Previously, lutein was encapsulated into
various nano-formulations such as polymeric nanoparticles (PLGA, Polyvinyl pyrrolidone),
liposomes, nano-emulsions, nanocrystals, lipid nano-capsules, and nano-dispersions. Nanoformulations of lutein were evaluated by in vitro studies and animal models for anti-oxidant, antiinflammatory, anti-cancer, cognitive defects, and acute macular degeneration (Lim et al. 2016;
Tan et al. 2016; Muhoza et al. 2018; Mitri et al. 2011; Steiner, McClements, and Davidov-Pardo
2018; do Prado Silva et al. 2017; Brum et al. 2017). The aim of the present study was to encapsulate
lutein into polymeric nanoparticles (PLGA and PLGA-PEG-FOLATE) and evaluate its enhanced
uptake in neuroblastoma cells.
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Materials and Methods
Materials
Lutein (90%) was obtained from Acros Organics (New Jersey, USA). Dimethyl sulfoxide
(DMSO), methanol (HPLC grade), tetrahydrofuran (HPLC grade), dichloromethane (DCM), nhexane, sodium chloride, and potassium dihydrogen phosphate were procured from Fisher
Scientific (Fair Lawn, NJ, USA). Sodium dodecyl sulphate, polyvinyl alcohol (PVA) (MW: 30,000
- 70,000), and disodium hydrogen phosphate were purchased from Sigma Aldrich (St. Louis, MO,
USA). Milli-Q water (18.2 MΩ resistivity) was from Milli-Q® IQ 7000 Ultrapure Water System
(EMD Millipore, Bedford, MA, USA). PLGA (50:50, MW: 10,000 – 15,000) and PLGA-PEGFOLATE (50: 50; MW: 10,000 Da-2,000 Da) were procured from Akina PolySciTech, Inc,
Indiana, USA. Fluorescein isothiocyanate (FITC) was purchased from Invitrogen, Labeling &
Detection, Molecular Probes, ThermoFisher Scientific, USA. Cellulose ester dialysis tubing
(Biotech grade; Mw: 300 kDa) was obtained from Spectrum Laboratories, Inc (CA, USA). Human
neuroblastoma cell line, SK-N-BE(2) (ATCC CRL-2271), was purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA).
Methods
Preparation of polymeric Nanoparticles loaded with lutein
Lutein loaded polymeric nanoparticles were prepared using a slightly modified oil in water
(O/W) emulsion-solvent evaporation method reported earlier (Figure 3.1) (Jwala et al. 2011; Sai
HS. Boddu, R. Vaishya, J. Jwala, A. Vadlapudi 2012). In brief, 100 mg of polymer (PLGA or
PLGA-PEG-FOLATE) was completely dissolved in 5 mL of DCM and lutein (20 mg) was
separately dissolved in 2 mL DCM. The polymer and lutein solutions were mixed to form a
homogenous organic phase. The organic phase was sonicated in a bath sonicator for 5 minutes
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followed by its slow addition to aqueous solution of PVA (2% w/v) (20 mL) under constant stirring
on a magnetic stirrer. Further, the resultant mixture was sonicated at 30% amplitude for 5 minutes
using a Fisher Scientific™ Model 505 probe sonicator to obtain an emulsion. The sonication step
was performed in cold conditions to prevent any overheating of the emulsion. After sonication,
emulsion was kept overnight under gentle stirring at room temperature to completely evaporate
DCM. The emulsion was washed three times with deionized water using Beckman ultracentrifuge
at 22,000 × g for 1 h to remove any unentrapped lutein and PVA residue. Finally, the nanoparticles
formed were lyophilized for 24 h using a benchtop freeze dryer (Harvest Right, North Salt Lake,
UTAH, USA) (vacuum: <100 mTorr and condenser temperature: −50 °C).

Figure 3.1: Oil in water emulsion-solvent evaporation method for preparation of lutein loaded
PLGA-PEG-FOLATE nanoparticles
Determination of particle size, PDI and ZP
The particle diameter, PDI of lutein loaded PLGA and PLGA-PEG-FOLATE nanoparticles
were measured using DLS technique. Zeta potential of nanoparticles was determined by measuring
electrophoretic mobility of particles using Malvern Zetasizer. NP dispersions (200 µL) were

33

further dispersed in double distilled de-ionized water (10 mL) and size and ZP were analyzed with
Malvern Zetasizer Nano ZS90 at 25 °C. All the measurements were performed on three different
samples (n = 3).
Determination of lutein encapsulation efficiency (%EE) and drug loading (%DL)
The encapsulation and loading of lutein into nanoparticles were determined by quantifying
the lutein content in freeze dried nanoparticles using high performance liquid chromatography
(HPLC). Briefly, freeze dried nanoparticles (10 mg) were dissolved in 10 mL DMSO and the
amount of lutein was determined using Waters Alliance e2695 HPLC equipped with 2998
photodiode array (PDA) detector and Empower 3.0 software. The separation was performed using
Kromasil® C-18 column (5 μm; 250 mm × 4.6 mm) under isocratic conditions at a flow rate of
1 mL/minute at 25 °C. Mobile phase used was methanol: tetrahydrofuran at a ratio of 90: 10 and
the analyte was monitored at 450 nm. Retention time of lutein was 3.85 minutes (Liu et al. 2014).
Sample injection volume was 20 µL and the run time was 10 mins. The %EE and %DL of lutein
in the nanoparticles was determined using the following formulae. All the measurements were
performed on three different samples (n = 3).
%EE = (Amount of lutein remained in nanoparticles)/(Initial amount of lutein) × 100
Drug loading (%DL) = (Weight of lutein in nanoparticles)/(Weight of polymer used) × 100
DSC
Encapsulation of lutein into PLGA and PLGA-PEG-FOLATE was confirmed using DSC
technique. Calorimetric analysis was performed for lutein, PVA, polymers (PLGA and PLGAPEG-FOLATE), and lutein loaded nanoparticles using DSC822e (Mettler Toledo) instrument.
Samples were weighed (3-11 mg) accurately in 40 µL capacity aluminum pans and were
hermetically sealed using a crimping device. Reference standard was an empty aluminum pan on
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the other side. Nitrogen was purged at a rate of 20 mL/minute during the analysis. Samples were
held at 25 °C isotherm for 5 minutes and then heated at 10 °C/minute to 280 °C. All the
thermograms recorded were analyzed using STARe software.
Fourier Transform Infrared Spectroscopy (FTIR)
The FTIR spectra of lutein, PVA, polymers (PLGA and PLGA-PEG-FOLATE), and lutein
loaded polymeric nanoparticles were recorded on a JASCO-FT/IR 4600 instrument using
Attenuated Total Reflection (ATR) technique. Sample compartment was flushed with argon prior
to each run. The sample was ground to fine powder with a KBr pellet. The scanning range was
from 500 – 4000 cm−1. After the spectrum measurement, the spectral data were analyzed and
plotted, CO2 and H2O peaks were subtracted from the original spectrum to obtain the final IR
spectrum.
Surface Morphology
Quanta 600F scanning electron microscope with a high-resolution field emission source
(ThermoFisher Scientific, Hillsboro, OR) was used to study the surface morphology of lutein
loaded nanoparticles. Freeze dried nanoparticles suspended in milli-Q water were deposited on a
copper grid and fixed with double-sided conductive tape. nanoparticles were coated with gold
using a gold sputter [Precision Etching and Coating System (Gatan 682 PECS) (Gatan, Inc.,
Pleasanton, CA)] and allowed to evaporate. High resolution images of the nanoparticles were
visualized under high vacuum at an accelerated voltage of 20 kV.
In vitro release studies
Initially, various media were screened to identify the most suitable release medium for
studies. Release media which were screened included phosphate buffered saline 7.4 with 0.2% w/v
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sodium dodecyl sulphate, 20% (v/v) ethanol and phosphate buffered saline 7.4 with 0.2% w/v
sodium dodecyl sulphate and 20% v/v ethanol. Excess lutein (~20 mg) was added to 2 mL of
release medium in Eppendorf tubes (2 mL capacity) and were placed in a shaking water bath
(100 rpm) at 37 °C. After 24 hours, samples were removed from the water bath and filtered through
0.45 µm cellulose acetate syringe filter. Aliquots of filtrate were diluted appropriately to determine
the saturation solubility of lutein in release medium. After selecting the release medium, drug
release behavior from lutein loaded PLGA and PLGA-PEG-FOLATE nanoparticles was
determined using dialysis bag method (MWCO: 300 kDa) (Joseph et al. 2018). Phosphate buffered
saline (pH 7.4) with 0.2% w/v sodium dodecyl sulphate was chosen as the suitable release medium
for release studies to maintain sink conditions (Hu et al. 2012). In brief, 1 mL lutein loaded
polymeric nanoparticles (~1 mg lutein) were transferred to individual dialysis tubing and release
medium (1 mL) was added to the tubings. Leakage was prevented by sealing the tubing tightly at
both ends. Sealed dialysis tubings loaded with nanoparticles were transferred to 250 mL beakers
containing 100 mL of release medium in a shaking water bath (100 rpm) (maintained at 37 ± 0.5
°C). To prevent any evaporation of release medium, beakers were packed tightly with parafilm. At
a pre-determined time-intervals (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 24, and 48 h), samples (10 mL) were
collected from each beaker and replaced with 10 mL of fresh release medium. Cumulative amount
of drug released from the formulations was quantified using UV spectrophotometer (UV 1800,
Shimadzu, Kyoto, Japan) by measuring the absorbance at λmax of 436 nm at different timepoints.
All experiments were performed on three different samples (n = 3).
Cell Culture studies
Neuroblastoma (SK-N-BE(2)) cells were used in this study to determine the cellular uptake
of lutein loaded PLGA-PEG-FOLATE nanoparticles as compared to lutein and lutein loaded
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PLGA nanoparticles. SK-N-BE(2) cells were purchased from ATCC (American Type Culture
Collection, Virginia, USA) and were cultured according to manufacturer’s protocol. In brief,
DMEM: F-12 (1:1 ratio) culture media containing 10% (v/v) heat inactivated fetal bovine serum
(FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin, 1% (v/v) MEM Non-essential amino
acids and 1% sodium bicarbonate was used for culturing SK-N-BE(2) cells. The cells were grown
in T-75 Corning culture flask and incubated at 37 °C, 5% CO2, and 95% relative humidity.
FITC Labelling
The cellular distribution of lutein loaded PLGA-PEG-FOLATE nanoparticles, lutein
loaded PLGA nanoparticles and lutein was determined by labeling various treatment groups with
FITC. FITC is widely used to label proteins (Chaganti, Venkatakrishnan, and Bose 2018), drugs
(Michlewska et al. 2019) and polymers (Damgé, Maincent, and Ubrich 2007). FITC labeling was
performed according to a previously published protocol (Mandal et al. 2017). Briefly, 10 µg
equivalent of lutein loaded PLGA-PEG-FOLATE nanoparticles and PLGA nanoparticles were
suspended in 50 mM phosphate buffered saline to make a 10 µg/mL of suspension of the
nanoparticles. The final volume of the suspension was 8.0 mL. Separately, powdered FITC was
dissolved in DMSO (1 mg/mL) since, FITC was not water soluble. The freshly prepared FITC
solution (1.0 mL) was added to nanoparticles suspension (8.0 mL) and incubated at 4º C in dark
for 12 hours. The incubation was followed by addition of 1 mL 50 mM ammonium chloride
(NH4Cl) to inactivate any unreacted FITC. Finally, the FITC labelled nanoparticles solution was
subjected to dialysis using a 2,000 kDa dialysis filter to remove unreacted FITC, and other small
molecules (NH4Cl). Finally, the formulation was filtered through a 0.22 µm nylon syringe filter to
ensure sterility of the FITC labelled nanoparticles. This fluorescent labelled nanoparticle solution
was then aliquoted, protected from light and stored at -20°C until further use. A solution of FTIC
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labelled lutein was also prepared in similar way as described above, except lutein was dissolved
in DMSO (5 mg/mL) and then mixed with FITC solution.
In vitro uptake determination using flow cytometry [Fluorescence-activated cell sorting
(FACS)]
The cellular uptake of FITC labelled nanoparticles in SK-N-BE(2) cells was determined
by incubating the cells with the fluorescent treatment groups and then analyzing their timedependent uptake using flow cytometry (FACS). SK-N-BE(2) cells were seeded in a 12-well plate
at a density of 0.5 × 106 cells/well with 1 mL of DMEM: F-12 media and stored overnight in an
incubator maintained at 37 ºC, 5% CO2 and 95% RH. The overnight incubation was followed by
treating the cells with 10 µL of various treatment groups which included (i) Control (DMSO), (ii)
FITC-lutein PLGA nanoparticles and (iii) FITC-lutein PLGA-PEG-FOLATE nanoparticles. Then,
the treated SK-N-BE(2) cells were incubated for various pre-determined time points (3, 6, 9, and
12 hours), which was followed by harvesting the cells, washing and acquiring the samples with
FACS. At each time point, the media was removed from the wells and the cells were harvested
using 200 µl of trypsin (TrypLE). This was followed by incubation (5 minutes) and addition of
serum containing DMEM: F-12 media. The cells were then collected in FACS tubes and
centrifuged at 20,000 rpm for 5 minutes to a obtain cell pellet. Further, the media was discarded,
and the cells were washed twice with 1 mL of Dulbecco's Phosphate-Buffered Saline (DPBS)
(Gibco's). The final sample was prepared using DPBS and acquired by flow cytometry to
determine the mean FITC fluorescence intensity of the cells at an excitation wavelength of 490
nm. The mean FITC fluorescence intensity values obtained for all the samples were plotted using
bar-graphs in GraphPad Prism (version 5.0) and the differences were observed.
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In vitro uptake determination by confocal microscopy
Confocal laser scanning microscopy (CLSM) was used to determine the cellular
distribution of FITC labelled nanoparticles and lutein in SK-N-BE(2) cells. FITC-lutein-PLGAPEG-FOLATE nanoparticles, FITC-lutein PLGA nanoparticles and FITC-lutein were prepared
using the same method described in earlier sections and were used as treatment groups. The
unreacted FITC in all the samples was removed by adding 1 mL 50 mM NH4Cl. FITC was
adsorbed on the surface of the nanoparticles. SK-N-BE(2) cells were seeded in a 8- chamber
confocal microscopy slide precoated with collagen (Nunc Lab-Tek 8 chambered, Thermo Fisher
Scientific, Waltham, MA, USA) and 200 µL of complete DMEM: F-12 (1:1) media. These slides
were stored overnight in an incubator maintained at 37 ºC, 5% CO2 and 95% R.H. This was
followed by addition of 10 µL various treatment samples which included (i) control (DMSO), (ii)
FITC-lutein, (iii) FITC-lutein PLGA nanoparticles, and (iv) FITC-lutein-PLGA-PEG-FOLATE
nanoparticles into each chamber of the 8-chamber plate. Further, the treatment groups were
incubated for 6 and 12 hours. At each time point, the culture media was removed, and the cells
were washed twice with 300 µl of DPBS for 5 minutes. This was followed by fixing the cells with
freshly prepared cold 4% buffered paraformaldehyde solution (200 µl) and incubation at 37 ºC for
20 minutes. After incubation, the fixation solution was removed, and the cells were washed again
with 300 µl DPBS (3 times × 5 minutes each). Further, the nuclei of the cells were stained with
100 µl of DAPI (working solution of 10 µg/mL) for 15 minutes in dark. The cells were then
mounted with mounting media and a sealed cover slip to prevent evaporation of the mounting
media and dehydration of the cells. The SK-N-BE(2) cell slides were stored at 4ºC before the
actual analysis. A Leica Confocal Laser Scanning Microscope (Leica TCS SP5, Wetzlar,
Germany) was used to analyze the cells for green fluorescence-FITC and blue fluorescence-DAPI.
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Determination of cellular uptake of lutein using HPLC
Cellular uptake studies were conducted in SK-N-BE(2) (ATCC CRL-2271), human
neuroblastoma cell line. Cells were grown as described in previous sections and maintained in a
humidified atmosphere with 95% air and 5% CO2. Cells were seeded at a density of 106 cells/well
in six-well plates for 24 h before treatment. After 24 h, the uptake study was initiated by adding
lutein nano-formulation (1 mL) containing 20 µg of lutein to the wells and placed in an incubator
maintained at 37 °C for 12 h. After incubation, the cells were washed two-times with phosphate
buffered saline and supernatant was separated. Then, cells from the wells were lysed in 0.5 mL
phosphate buffered saline with a microtube homogenizer. To extract lutein from the lysed cell
suspension, 1.5 mL of DCM and methanol solution (1:2) was added to the suspension and mixed
using vortex mixer for 5 minutes. Then, hexane (2 mL) was added to the mixture, and the resultant
hexane-DCM layer (supernatant) was separated and dried to get lutein extract. The lower layer
was similarly extracted twice. The extracted lutein was re-dissolved in 400 µl of methanol:
dichloromethane (4:1) solution and analyzed using HPLC.
Physical stability Studies
A 60-day physical stability studies were conducted for all the nanoparticles at 4 °C and 25
°C. All nano-formulation dispersions were stored in glass scintillation vials for 60 days. At days
0, 30 and 60, all the samples were re-dispersed in milli-Q water (18.2 MΩ resistivity), and assessed
for particle size, PDI, ZP using Malvern Zetasizer.
Statistical analysis
Statistical analysis was done using GraphPad Prism® software (Version 5.0, San Diego,
CA). A non-parametric t-test followed by Bonferroni's multiple comparison post-test was used to
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compare cellular uptake of nano-formulations. A 2-way analysis of variance (ANOVA) followed
by Bonferroni’s post-test was applied for stability studies.
Results and Discussion
Preparation and characterization of lutein loaded nanoparticles
PLGA and PLGA-PEG-FOLATE were chosen for the formulation of nanoparticles due to
the biocompatibility, biodegradability, mechanical strength, targetability, and versatile
biodegradation kinetics (Jain 2000; Mu and Feng 2003; Sahana et al. 2008). PLGA is metabolized
to form safe degradation products such as lactate and glycolic acid, which are removed by Kreb’s
cycle. PVA was used for formulation of nanoparticles as it is the most widely used stabilizer for
emulsions and helps in forming nanoparticles with smaller size and uniform size distribution (Turk
et al. 2014). Moreover, both PLGA and PVA are US FDA approved inactive ingredients in various
formulations (Mu and Feng 2003; Sahana et al. 2008). The size, PDI, and ZP of lutein loaded
polymeric nanoparticles is provided in Table 3.1. Results show that all the lutein loaded
nanoparticles had size < 200 nm with uniform size distribution (Figure 3.2). Size of lutein PLGA
and PLGA-PEG-FOLATE nanoparticles were 189.6 ± 18.79 nm and 188.0 ± 4.06 respectively.
PDI ranged from 0.083 ± 0.023 to 0.202 ± 0.009. ZP is a measurement of the surface charge on
the nanoparticles and is a representative of stability of the nanoparticles (Suttiponparnit et al.
2010). Zeta potential results revealed that lutein loaded PLGA-PEG-FOLATE nanoparticles had
higher ZP (-26.0 ± 1.27 mV) compared to lutein loaded PLGA nanoparticles (-10.7 ± 1.80 mV).
Terminal carboxylic groups in the polymers is responsible for the negative ZP values (Sai HS.
Boddu, R. Vaishya, J. Jwala, A. Vadlapudi 2012; Esmaeili et al. 2008), which could be a reason
for higher shift of ZP of PLGA-PEG-FOLATE towards negativity.
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Table 3.1: Size, PDI, ZP and %EE of lutein loaded PLGA and PLGA-PEG-FOLATE
nanoparticles (n = 3). Data are expressed as mean ± SD

S.no

Particle type

Size (nm)

PDI

ZP (mV)

%EE

1

Lutein PLGA

189.6 ± 18.79

0.083 ± 0.023

-10.7 ± 1.80

60.95 ± 4.85

2

Lutein PLGA-PEG-

188.0 ± 4.06

0.202 ± 0.009

-26.0 ± 1.27

72.87 ± 7.22

FOLATE

Figure 3.2: Size distribution curves of A) Lutein-PLGA and B) Lutein PLGA-PEG-FOLATE
nanoparticles
%EE and %DL
The %EE of lutein was 60.95% ± 4.85% and 72.87% ± 7.22% for lutein PLGA and PLGAPEG-FOLATE nanoparticles, respectively (Table 3.1). The lutein loading in PLGA and PLGAPEG-FOLATE nanoparticles was ~12.2% and ~14.6%, respectively. Results showed that folate
decorated nanoparticles had greater lutein encapsulation compared with PLGA nanoparticles.
Greater encapsulation with PLGA-PEG-FOLATE polymer can be due to the presence of folate on
the surface of nanoparticles, which could have increased the interaction between lutein and the
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polymer. Similar results were obtained when docetaxel and SN-38 were encapsulated in folate
decorated nanoparticles (Esmaeili et al. 2008; Ebrahimnejad et al. 2010).
Surface Morphology
SEM is one of the most widely used technique for understanding the surface morphology
of nanoparticles. High resolution images of the nanoparticles were obtained using electron beam
as a probe (Tsaousis et al. 2018). SEM images of lyophilized lutein loaded polymeric nanoparticles
are shown in Figure 3.3. These images revealed that the nanoparticles were spherical in shape. The
sizes obtained from the SEM images of all nanoparticles were below 200 nm and are well
corroborated with the DLS results.
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Figure 3.3: SEM images of Lutein-PLGA nanoparticles (A and B) and Lutein- PEG-PLGA FOLATE nanoparticles (C and D). Scale bars are 1 µm for (C), 3 µm for (A) and 5
µm for (B and D).
DSC
DSC is one of the widely employed techniques to determine the polymorphic changes of
the drugs and polymers in formulation research. Thermograms of lutein, polymers and lutein
loaded nanoparticles are provided in Figure 3.4. Lutein had a sharp characteristic endothermic
peak at 64.07 °C as per the thermogram. Also, PLGA had an endothermic at 45.28 °C. On the
other hand, no specific peak/melting point was observed for PLGA-PEG-FOLATE and PVA
confirming the amorphous nature of the polymers. The characteristic endothermic peak of lutein
disappeared in thermograms of lutein loaded nanoparticles thereby confirming the complete
encapsulation of lutein into the amorphous polymers. Transformation of lutein from crystalline
form to amorphous form is important as amorphous forms are characterized with higher solubilities
and increased bioavailability compared to crystalline forms (K. P. Bolla et al. 2019; Morissette et
al. 2004; Kalhapure and Akamanchi 2013). Similar results (loss of characteristic peak) were
obtained in other studies where crystalline drugs such as oxcarbazepine, prilocaine, and adefovir
were encapsulated into PLGA micro and nanoparticles (Musumeci et al. 2018; Bragagni et al.
2018; Ayoub et al. 2018). Overall, DSC results confirmed the successful encapsulation of
crystalline lutein into amorphous polymeric nanoparticles.
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Figure 3.4: DSC thermograms of (A) lutein loaded PLGA-PEG-FOLATE nanoparticles, (B)
PLGA-PEG-FOLATE, (C) lutein loaded PLGA nanoparticles, (D) Lutein, (E)
PVA, and (F) PLGA.
FTIR analysis
The surface chemistry of lutein, PVA, PLGA, PLGA-PEG-FOLATE, lutein loaded PLGA
and PLGA-PEG-FOLATE nanoparticles was evaluated using FTIR spectroscopy (Figure 3.5). The
broad transmittance band of lutein between 3588.88 cm−1 and 3073.01 cm−1 corresponds to the OH stretching vibrations, which was absent in lutein loaded PLGA and PLGA-PEG-FOLATE
nanoparticles. In addition, characteristic C-H stretching bands at 2958 cm-1 and 2912 cm-1 were
observed for lutein. A strong transmittance of lutein was observed at 1620.15 cm−1 which was
absent in the spectra of the lutein-loaded PLGA-PEG-FOLATE and PLGA nanoparticles. There
was no obvious difference in the spectra of the polymers (PLGA and PLGA-PEG-FOLATE) and
lutein loaded polymeric nanoparticles. FTIR spectra obtained for PLGA-PEG-FOLATE in our
study was similar to the spectra available in the literature (Fasehee et al. 2016; Sai HS. Boddu, R.
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Vaishya, J. Jwala, A. Vadlapudi 2012). Results from FTIR confirm showed that the characteristic
peaks of lutein were absent in the FTIR spectra of lutein loaded polymeric nanoparticles. This
could be due to the strong interaction of lutein with the polymers which resulted in the absence of
characteristic peaks. Similar results were observed for other nanoparticle systems (Ahlawat,
Deemer, and Narayan 2019). Moreover, it is evident that the encapsulation of lutein into polymers
did not result in any structural changes which might be attributed to either the small concentration
of the drug or due to its bonding and non-bonding interactions with the surrounding matrix.

Figure 3.5: Fourier-transform infrared spectroscopy (FTIR) spectra of PLGA, PLGA-PEGFOLATE, lutein loaded PLGA and PLGA-PEG-FOLATE nanoparticles, PVA and
lutein.
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In vitro release studies
After analyzing the solubility of lutein in various release media, phosphate buffered saline
7.4 with 0.2% sodium dodecyl sulphate was chosen as the release medium (Hu et al. 2012). In vitro
release profile of lutein from PLGA and PLGA-PEG-FOLATE nanoparticles is provided in Figure
3.6. Release profiles showed that the nano-formulations showed initial burst-release (~50% and
~43% with PLGA and PLGA-PEG-FOLATE nanoparticles in 6 h), followed by sustained release
pattern. Cumulative release of lutein was higher in PLGA nanoparticles with 100% release within
24 hours and ~80% in PLGA-PEG-FOLATE nanoparticles at 48 h. Similar release profiles were
reported in literature when drugs such as SN-38 and docetaxel were encapsulated in folate
decorated nanoparticles. The lower release of lutein from PLGA-PEG-FOLATE nanoparticles can
be attributed to the high affinity of drug with the polymer or densely packed polymer system with
low porosity, which hinders the immediate release of drug from the nanoparticles and also due to
better arrangement of lutein in polymer matrix (Esmaeili et al. 2008; Ebrahimnejad et al. 2010; Sai
HS. Boddu, R. Vaishya, J. Jwala, A. Vadlapudi 2012). Moreover, higher encapsulation of lutein
in the PLGA-PEG-FOLATE polymer could have resulted in lesser space for polymer hydration
and leading to slower release of lutein (Kamaly et al. 2016). Overall, release studies validate the
sustained/controlled release of drugs from polymeric nanoparticles.
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Figure 3.6: In vitro release of lutein loaded PLGA and PLGA-PEG-FOLATE nanoparticles. Data
are expressed as mean ± SD (n=3).
In vitro cellular uptake studies
In vitro cellular uptake of lutein was determined in SK-N-BE(2) neuroblastoma cell line to
understand the intracellular localization and uptake of the folate decorated nanoparticles loaded
with lutein as compared to lutein PLGA nanoparticles and plain lutein. These studies also helped
to compare the uptake of the lutein nanoparticles within the cytoplasm of SK-N-BE(2) cells. FACS
and confocal microscopy were used as quantitative and a qualitative analysis method respectively,
to determine the cellular uptake. Further, enhanced uptake of lutein with PLGA-PEG-FOLATE
polymer was also determined by measuring the amount of lutein uptaken using HPLC.
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FACS Analysis
FITC- labelled-lutein loaded nanoparticles were incubated with SK-N-BE(2) cells and
were analyzed to determine in vitro uptake at predetermined time points by using flow cytometry.
Figure 3.7 depicts the time dependent uptake of FITC-labelled nanoparticles in SK-N-BE(2) cells
as measured by the mean FITC fluorescence intensity. Results show that there was a significant
increase in the uptake of FITC-lutein-PLGA-PEG-FOLATE nanoparticles as compared to FITClutein PLGA nanoparticles at 6 hours and 9 hours. This enhanced uptake could be attributed to the
receptor mediated endocytosis due to the presence of folate receptors on the surface of the SK-NBE(2) cells, which aid in the higher uptake of the folate decorated lutein nanoparticles.

Mean FITC Fluroscence Intensity

8000

Control

Lutein PLGA NPs

Lutein PLGA-PEG-FOLATE NPs
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4000

2000

0
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Figure 3.7: FACS analysis of lutein loaded polymeric nanoparticles (PLGA and PLGA-PEGFOLATE) for 3-, 6-, 9-, and 12 hours. in SK-N-BE(2) cells. Data are represented as
mean ± SEM.
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Confocal microscopy
In vitro cellular uptake of FITC labelled lutein nanoparticles (PLGA and PLGA-PEGFOLATE) and FITC labelled lutein was performed using confocal laser scanning microscopy for
visual representation and qualitative analysis of lutein uptake by SK-N-BE(2) cells. The cells were
incubated with the treatment groups for 6 and 12 hours. At the end of each time point the cells
were washed, fixed, stained with DAPI and mounted on a slide for visualization by confocal laser
scanning microscopy. Figure 3.8 and Figure 3.9 depicts the in vitro uptake of lutein nanoparticles
(PLGA and PLGA-PEG-FOLATE) and FITC labelled lutein at 6 h and 12 h, respectively. It can
be observed clearly that the fluorescence for FITC increases in all the treatment groups with time.
It is also interesting to note that at all timepoints, the fluorescence in the cells treated with FITClabelled lutein loaded polymeric nanoparticles (PLGA and PLGA-PEG-FOLATE) was higher than
FITC- labelled lutein. These results are well corroborated with the results from the FACs analysis.
This can imply that folate decorated lutein nanoparticles and lutein PLGA nanoparticles are well
absorbed via the lipid bilayer of SK-N-BE(2) cells as compared to the free drug (lutein). Thus, the
rate of internalization for lutein nanoparticles (PLGA and PLGA-PEG-FOLATE) into the
cytoplasm and nuclei was higher than the drug alone. In addition, at 6-hour and 12- hour
timepoints, a stronger fluorescence was observed with lutein loaded PLGA-PEG-FOLATE
nanoparticles compared to lutein loaded PLGA nanoparticles. Thus, the results from confocal laser
scanning microscopy analysis also confirm the greater uptake of lutein into the cells with lutein
loaded PLGA-PEG-FOLATE nanoparticles through the folate receptor mediated endocytosis.
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Figure 3.8: Confocal laser scanning microscopy images of FITC-labelled lutein and FITClabelled lutein polymeric nanoparticles (PLGA and PLGA-PEG-FOLATE) at 6
hours in SK-N-BE(2) cells

51

Figure 3.9: Confocal laser scanning microscopy images of FITC-labelled lutein and FITClabelled lutein polymeric nanoparticles (PLGA and PLGA-PEG-FOLATE) at 12
hours in SK-N-BE(2) cells.
Cellular uptake studies using HPLC
In vitro cellular uptake studies were conducted to evaluate the enhanced uptake of lutein
from folate decorated nanoparticles in neuroblastoma cells. Neuronal cells after terminal
maturation cannot be propagated in vitro. Neuroblastoma cell lines have been extensively used to
study various neuronal properties including drug uptake studies (Lashford, Hancock, and
Kemshead 1991; Walton et al. 2004). Results revealed that there was a significant increase uptake
of lutein with PLGA-PEG-FOLATE nanoparticles compared to PLGA nanoparticles and plain
lutein (p < 0.05). There was ~1.6 fold and ~2-fold enhanced uptake of lutein from PLGA-PEG52

FOLATE nanoparticles compared with PLGA nanoparticles and plain lutein, respectively. The
amount of lutein accumulated in the cells was 3.32 μg, 4.03 μg, and 6.5 μg for plain lutein, lutein
loaded PLGA and PLGA-PEG-FOLATE nanoparticles, respectively (Figure 3.10). Thus,
increased uptake of lutein was observed with folate decorated nanoparticles in neuroblastoma cells
compared to plain lutein and lutein PLGA nanoparticles. Enhanced lutein uptake with PLGA-PEGFOLATE polymer can be attributed to the hydrophilicity of folate at physiological conditions,
which leads to receptor mediated uptake through folate receptors. Similar results of enhanced drug
uptake were observed with folate decorated liposomes and PLGA nanoparticles loaded with
doxorubicin and etoposide for brain tumors (Guo et al. 2017). We do know that lutein carried in
lipoproteins (natural nanoparticles) cross blood - epithelial barriers (Thomas and Harrison 2016).
Also, folate receptors are abundant in the blood brain barrier (BBB) (Wu and Pardridge 1999; Guo
et al. 2017). It is also known that newborn babies tolerate lutein well and they naturally accumulate
in the brain if supplemented (Vishwanathan et al. 2014). A synthetic biologic nanoparticle rich in
lutein with capabilities to cross BBB and increase targeted delivery to brain during hypoxiaischemia would be valuable. Another interesting prospect is in preterm newborn brain injury which
is predominant and where lutein transport mechanisms are less effective (Costa et al. 2013;
Giampietri et al. 2016).
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Figure 3.10: In vitro cellular uptake of lutein using plain lutein, lutein PLGA nanoparticles and
lutein PLGA-PEG-FOLATE nanoparticles in SK-N-BE(2) cells.
Physical stability studies
Lutein loaded polymeric nanoparticles were evaluated for physical stability for 60 days
stored at 4 °C and 25 °C. The effects of storage on the particle diameter, PDI and ZP of lutein
loaded polymeric nanoparticles is provided in Table 3.2. Results revealed that there was no
significant change in the particle diameter, PDI and ZP of lutein loaded nanoparticles from day 1
to days 30 and 60 with both the polymers at 4 °C and 25 °C (p > 0.05) (Figure 3.11). Similarly,
there was a no signs of aggregation of nanoparticles. Physical stability results confirmed that lutein
loaded PLGA-PEG-FOLATE nanoparticles were stable at 4 °C and 25 °C over the period of 60
days.
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Table 3.2: Effect of storage on PDI and ZP of lutein polymeric nanoparticles at 4 °C and 25 °C.

PDI
Time

Lutein PLGA

Lutein PLGA-

(Days)

1

30

60

ZP (mV)
Time (Days)

Lutein PLGA

PEG-FOLATE
4 oC

25 oC

4 oC

25 oC

4 oC

25 oC

4 oC

25 oC

0.083 ±

0.104 ±

0.202 ±

0.202 ±

-10.7 ±

-10.7 ±

-26.0 ±

-26.0 ±

0.023

0.056

0.009

0.009

1.80

1.80

1.27

1.27

0.112 ±

0.063 ±

0.202 ±

0.148 ±

-9.16 ±

-13.8 ±

-24.5 ±

-31.7 ±

0.043

0.04

0.013

0.123

2.09

1.93

2.50

7.70

0.053 ±

0.113 ±

0.190 ±

0.394 ±

-12.7 ±

-12.5 ±

-21.3 ±

-22.7 ±

0.021

0.046

0.027

0.068

0.73

2.22

1.10

2.69
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Figure 3.11: Effect of storage on particle diameter of lutein loaded polymeric nanoparticles at 4
°C and 25 °C
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Conclusions
Encapsulation of hydrophobic drugs into polymeric nanoparticles can significantly
enhance the bioavailability and release the drugs in sustained manner. In this study, lutein was
successfully encapsulated into PLGA-PEG-FOLATE nanoparticles and significantly enhanced the
lutein uptake in neuroblastoma cells. There was ~1.6 fold and ~2-fold enhanced uptake of lutein
from PLGA-PEG-FOLATE nanoparticles compared with PLGA and lutein alone. Confocal
microscopy and flow cytometry analysis also confirmed the enhanced uptake of lutein with lutein
loaded PLGA-PEG-FOLATE nanoparticles. Size of lutein loaded PLGA-PEG-FOLATE
nanoparticles was <200 nm with high %EE of >70%. SEM results confirmed the spherical surface
morphology of the nanoparticles. Sustained release of lutein from nanoparticles was confirmed by
in vitro release studies. Stability studies confirmed that there was no sign of NP aggregation within
60 days at 4 °C and 25 °C. Findings from this study confirmed the enhanced uptake of lutein from
PLGA-PEG-FOLATE nanoparticles in neuroblastoma cells. However, these results are
preliminary and enhanced uptake and neuroprotective properties of lutein from PLGA-PEGFOLATE nanoparticles will be confirmed in rat model of HIE.
Future studies
In this dissertation project, I have successfully prepared and characterized lutein loaded
folate decorated polymeric nanoparticles for enhancing the bioavailability of lutein in brain.
Enhancement of lutein uptake in brain cells could result in effective treatment of HIE. Future
studies include: (1) Investigation of neuroprotective effects of lutein loaded PLGA-PEG-FOL
nanoparticles in neonatal HIE rat model (2) Evaluation of pharmacokinetics and tissue distribution
of lutein loaded PLGA-PEG-FOL nanoparticles in vivo.
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Chapter 4: Preparation of Solid Lipid Nanoparticles of Furosemide-Silver Complex and
Evaluation of Antibacterial Activity
Graphical abstract

Illustration 4.1: Solid lipid nanoparticles of furosemide silver complex
Introduction
Antibiotics also referred to as “wonder drugs” have transformed the field of medicine by
effectively treating microbial infections. They act mainly by inhibition of several important
cellular processes such as cell wall and protein synthesis, and ultimately leading to bacterial cell
death (Davies and Davies 2010; Richardson 2017). However, antibiotic resistance is one of the
major challenges faced by the pharmaceutical and healthcare industries worldwide. Development
of resistance can limit the efficacy of antibiotics (Ventola 2015b). Resistance to antibiotics can be
developed by several biochemical, physiological and genetic mechanisms such as the development
of efflux pumps, genetic mutations, inhibition of drug uptake, and alteration of drug target, etc.
(Davies and Davies 2010). According to Center for Disease Control (CDC), the annual incidence
of resistant infections is about 2 million and among these 23,000 patients die due to these
infections. Economic burden due to antibiotic resistance on US healthcare system alone is
20 billion dollars in direct costs and 35 billion dollars in indirect costs, annually (Centers for
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Disease Control and Prevention 2013). Overuse and misuse of antibiotics in clinics and poor new
antibiotic pipeline in pharmaceutical industries have contributed to the current antibiotic crisis
(Ventola 2015a; Centers for Disease Control and Prevention 2013). There has been a significant
decline in the approval of new antibiotics by Food and Drug Administration (FDA) over the past
three decades (Ventola 2015a; Spellberg et al. 2008). CDC has developed four core actions to
combat antibiotic resistance which include i) prevention of infections and spread of resistance to
micro-organisms, ii) tracking resistant bacteria, iii) improving the antibiotic use and iv)
development of novel antibiotics and diagnostic tools (Ventola 2015b; Centers for Disease Control
and Prevention 2013). Therefore, there is a need for the synthesis of new antibiotics with enhanced
antibacterial activity and with novel mechanisms of action (Spellberg et al. 2008). Although, there
have been attempts to develop novel antibiotics, regulatory barriers to their approval have limited
their availability in the market (Ventola 2015b).
Historically, metal complexes of several drugs have been reported as antimicrobial agents
and among these silver complexes have been most common ones. For example, silver sulfadiazine
has been used in the clinics as a prophylactic and treatment for bacterial infections associated with
skin burns (Rai, Yadav, and Gade 2009; Kalhapure et al. 2015; Marambio-Jones and Hoek 2010).
Also, silver complexes of metronidazole (Kalinowska-Lis et al. 2015), nimesulide (de Paiva et al.
2012) and clotrimazole (Kalhapure et al. 2015) have been reported as antimicrobial agents. Silver
complexes could be effective as broad-spectrum antibiotics due to their chemical nature.
Moreover, due to multiple mechanisms of action of silver, development of bacterial resistance to
silver complexes is difficult (Prabhu and Poulose 2012).
Lustri et. al., synthesized a novel antimicrobial, silver complex of furosemide (Ag-FSE),
which was reported to have antibacterial properties against Escherichia coli (E. coli),
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Staphylococcus aureus (S. aureus), and Pseudomonas aeruginosa (P. aeruginosa). However, its
poor solubility in water and majority of organic solvents could limit its antibacterial activity (Lustri
et al. 2017). Recently, there has been a report on formulation of nanosuspension of Ag-FSE, which
resulted in significant enhancement of solubility and antibacterial activity (Renukuntla 2018b).
Other approaches to enhance solubility of poorly water-soluble drugs include nanonization
techniques such as the formulation of nano-emulsions, solid lipid nanoparticles (SLNs), liposomes
and polymeric micelles (H. Chen et al. 2011; Khadka et al. 2014). Goal of this project was to
encapsulate Ag-FSE into SLNs for achieving controlled and sustained drug release over a period
of time.
SLNs are colloidal nanosized drug carrier systems (50 nm to 1000 nm in diameter) with
matrix structure to encapsulate drugs. They are prepared from lipids which are solid at room and
body temperature, and are stabilized using surfactants (Wissing, Kayser, and Muller 2004; GeszkeMoritz and Moritz 2016; Khadka et al. 2014). Compared to other formulations, SLNs offer
advantages such as controlled and sustained drug release, enhanced drug solubility and stability,
high drug payload, scale-up and, biocompatibility (Ghaffari et al. 2011; Hou et al. 2003; Potta et
al. 2010). Researchers were successful in preparation of SLNs for improving solubility, drug
loading and antimicrobial activity of drugs such as tretinoin (Ridolfi et al. 2012), ofloxacin (Xie
et al. 2011), cortisone (Westesen, Bunjes, and Koch 1997), tilmicosin (Wang et al. 2012), nisin
(Prombutara et al. 2012), vancomycin (Kalhapure et al. 2014), and amikacin (Ghaffari et al. 2011).
Also, it was reported that encapsulation of clotrimazole silver complex into SLNs resulted in
enhanced antibacterial activity against methicillin resistant S. aureus (MRSA) and S. aureus
(Kalhapure et al. 2015). Therefore, the present study aims to encapsulate Ag-FSE into SLNs and
evaluate its sustained and enhanced antibacterial activity.
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Materials and Methods
Materials
Furosemide was purchased from Acros Organics (New Jersey, USA). Silver nitrate
(AgNO3), potassium hydroxide (KOH), dimethyl sulfoxide (DMSO), and Buffer salt packets were
obtained from Fisher Scientific (Fair Lawn, NJ, USA). Kolliphor® RH 40 (RH 40), Kolliphor®
HS 15 (SHS 15), and Tween® 80 (Tween 80) were procured from Sigma Aldrich (St. Louis, MO,
USA). Powdered sucrose NF was obtained from PCCA (Houston, Texas, USA). Deionized water
(resistivity of 18.2 MΩ) used for all experiments was obtained from in-house Milli-Q® IQ 7000
Ultrapure Water System (EMD Millipore, Bedford, MA, USA). Glycerol monostearate (GMS)
and Poloxamer 188 were obtained from Alfa Aesar (Ward Hill, MA, USA). Bacterial strains were
obtained from the American Type Culture Collection (ATCC). Muller-Hinton Broth (MHB)
(CM0405) for bacterial cultures was obtained from Oxoid Microbiology Products, USA. Sterile
microtiter plates were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Methods
Synthesis of Furosemide Silver Complex (Ag-FSE)
Furosemide silver complex was synthesized using a previously reported method
(Illustration 4.2) (Renukuntla 2018b; Lustri et al. 2017). Briefly, aqueous solution (2 mL) of
AgNO3 (2.13 mM, 0.362 g) was added dropwise to methanolic solution of furosemide (0.704 g,
2.13 mM) (20 mL) and KOH (0.119 g, 2.13 mM) under stirring at 500 rpm on magnetic stirrer.
The reaction mixture was subjected to continuous stirring (500 rpm) at room temperature for 2h.
After 2h, the white precipitate was obtained by filtration, washed three times with cold water and
dried in vacuum desiccator for 24 hours at room temperature.
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Illustration 4.2: Synthesis of Ag-FSE complex
Preparation of SLNs
SLNs were prepared using hot homogenization and ultrasonication technique described in
the literature with slight modifications (Kalhapure et al. 2015). SLNs were prepared using GMS
as the lipid matrix. GMS has been reported previously in the preparation of SLNs for controlled
drug delivery (Mhango et al. 2017). Structurally, GMS is a fatty acid with a glycerol backbone and
amphiphilic properties. Due to amphiphilic properties, GMS can self-assemble in both oil and
water phases into various types of mesophases and stabilize emulsion systems. GMS is widely
used as emulsifier in pharmaceutical and cosmetic industries (Talele, Sahu, and Mishra 2018).
Moreover, GMS is biocompatible and biodegradable lipid with low melting point and high
lipophilicity making it safe for biological applications (Mhango et al. 2017). Various surfactants
(RH 40, SHS 15, Tween 80, and Poloxamer 188) at 1% concentration were screened during
preliminary studies to obtain SLNs with minimum particle size and poly dispersity index (PDI).
Based on these size results, surfactant was selected and other parameters such as surfactant
concentration, homogenization and sonication time were evaluated to obtain optimized SLNs. All
experiments were performed in three batches (n=3). In brief, GMS (200 mg) and Ag-FSE (20 mg)
were heated at 80 ± 2 °C in a hot water bath. To the lipid and drug mixture Poloxamer 188 solution
(1% w/v; 20 mL) heated separately at same temperature was added. This mixture was
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homogenized at 5000 rpm using Fisherbrand™ 850 homogenizer for 5 minutes and immediately
sonicated at 20% amplitude for 10 minutes with a probe sonicator (Fisher Scientific™ Model 505
Sonic Dismembrator). After sonication, emulsion was suddenly cooled to 20 °C in an ice bath.
Blank SLNs were prepared by same method and same conditions without Ag-FSE. SLNs were
freeze dried using powdered sucrose as a cryoprotectant. To freshly formulated Ag-FSE SLNs,
sucrose dissolved in milli-Q water was added and the mixture was subjected to freeze drying using
Freezone freeze dryer (Labconco, USA) for 24 hours.
Determination of size, poly dispersity index (PDI) and ZP
The size, PDI, and ZP of the SLNs were measured using DLS technique. SLNs (200 µL)
were dispersed in 10 mL of deionized water and measurements were obtained using Malvern
Zetasizer Nano ZS90 at 25 °C.
Encapsulation efficiency (EE%) and drug loading (DL%)
EE% of the SLNs was determined by ultrafiltration method (Kalhapure et al. 2015) using
centrifugal filter tubes with a molecular weight cut-off of 10 kDa (MWCO 10 kDa). Ag-FSE SLN
dispersion (500 µL) was transferred into centrifugal filter tubes and centrifuged at 10,000 rpm for
30 minutes at 20 °C. EE% was calculated by measuring the unencapsulated Ag-FSE in the filtrate
and compared it with the total amount of drug added in the formulation. 300 µL of the filtrate was
diluted to 3 mL with deionized water. Unencapsulated Ag-FSE was quantified by measuring
absorbance at λmax 277 nm using UV-visible spectrophotometer (Shimadzu, Kyoto, Japan) (Gulsun
et al. 2018). The regression equation used for calculations was y = 0.0486x + 0.0135 with a
linearity of 0.9995. All the determinations were performed in three batches (n=3). EE% and DL%
were calculated using the following formulae (Kalhapure and Akamanchi 2013).
Encapsulation efficiency (EE%) = (Weightinitialdrug – Weightfreedrug)/(Weightinitialdrug) × 100
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Drug loading (%) = (Weightinitialdrug – Weightfreedrug)/(Weightlipid) × 100
Where Weightinitialdrug is the weight of the Ag-FSE used, Weightfreedrug was the weight of
unencapsulated Ag-FSE in the formulation and Weightlipid was the weight of the lipid used in the
formulation.
SEM
Scanning electron microscope (Hitachi S- 4800 High Resolution Scanning Electron
Microscope) was used to determine the surface morphology of Ag-FSE SLNs. Lyophilized SLNs
were attached to a double-sided conductive tape on a stainless-steel stub and the SEM images were
visualized at an accelerating voltage of 2kV.
XRD analysis
XRD analysis was performed using PANanlytical’s X-ray diffractometer (PANanlytical’s
X’pert Pro Tokyo, Japan) equipped with X’Celerator high speed detector. XRD studies were
performed for Poloxamer 188, GMS, Ag-FSE SLN and Ag-FSE. Powdered samples were placed
on an aluminum sample holder and uniformly packed using a glass slide. Radiation source was
CuKα operated at 45 kV and 40 mA. All measurements were recorded with a continuous scanning
mode over a 2θ range of 5° to 70°.
DSC
DSC is the most frequently used technique to study recrystallization and melting properties
of any material/formulation (Kalhapure and Akamanchi 2013). DSC was performed using DSC
Q20 instrument with TA universal analysis software to obtain scans. Samples (5-10 mg) were
weighed using microbalance and placed in aluminum pans and sealed. DSC analysis was
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performed at a heating rate of 10 °C/minute over a range of 40 °C to 300 °C with a nitrogen flow
of 20 mL/min.
In vitro release studies
Drug release behavior from Ag-FSE SLNs and free drug (Ag-FSE) in phosphate buffer
saline (PBS) (pH 7.4) was evaluated using dialysis bag method (MW 8000 – 14,400 Da) (Mhango
et al. 2017). In brief, 1 mL Ag-FSE SLNs, Blank SLNs and Ag-FSE in PBS were transferred into
separate dialysis bags and 1 mL PBS was added to each tubing. Tubing’s were tied at both ends to
prevent any leakage. Dialysis tubing’s loaded with Ag-FSE SLNs, Blank SLNs, and Ag-FSE were
kept in conical tubes (50 mL capacity) containing 30 mL of PBS as release medium maintained at
37 ± 0.5 °C in a shaking water bath (100 rpm). 3 mL of the samples were collected from each
conical tubes at pre-determined time-intervals. Samples were replaced with 3 mL of fresh PBS to
maintain sink conditions. The pre-determined time intervals were 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 24, 48,
72, and 96 h. The amount of drug released from the formulations at different timepoints was
quantified using a UV-visible spectrophotometer (Shimadzu, Japan) at λmax of 277 nm using the
regression equation provided in earlier sections. All the experiments were performed in triplicate.
Physical stability Studies
Physical stability studies were conducted for the freeze-dried Ag-FSE SLNs at room
temperature (RT) and 4 °C for 60 days. All samples were stored in sealed glass scintillation vials
at RT and 4 °C for 60 days. Freeze dried Ag-FSE SLNs were re-dispersed in milli-Q water,
sonicated for 2 minutes and evaluated for size, PDI, ZP at days 1, 30 and 60.
In vitro anti-bacterial activity
Antibacterial activities of free Ag-FSE and Ag-FSE SLNs were evaluated using broth
microdilution against E. coli (ATCC25922), S. aureus (ATCC25923) and P. aeruginosa
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(ATCC27853) (Mhango et al. 2017). In brief, bacterial cultures were grown overnight in MHB at
37 °C in an incubator. After incubation, cell density of the bacterial cultures were adjusted to
0.5 Mcfarland. Each well of the 96-well microtiter plate was dispensed with 100 µL of the adjusted
bacterial cell suspension. Immediately after dispensing, Ag-FSE SLNs, Ag-FSE in 10% w/v
DMSO, Blank SLNs and MHB were serially diluted in each well so that the final volume of each
well was maintained at 100 µL. The 96-well microtiter plates were incubated at 37 °C for 18 h and
the minimum inhibitory concentration (MIC) was assessed as the concentration at which no
bacterial growth was observed. Blank SLNs and MHB and 10% DMSO were used as controls. All
the experiments were performed in triplicate (n=3).
Statistical analysis
Data are expressed as the mean ± standard deviation (SD). Statistical analysis was
performed using GraphPad Prism® (Version 5.0, San Diego, CA). T-test followed by Bonferroni's
multiple comparison test was used for optimizing the blank SLN formulations. A two-way
ANOVA followed by Bonferroni posttest was applied for stability studies. A p value <0.05 was
considered as statistically significant.
Results and Discussion
Optimization of blank SLNs
Screening of surfactants
The experiments were aimed to obtain blank SLNs with particle sizes < 200 nm. SHS 15,
RH 40, Tween 80 and Poloxamer 188 at 1% concentration were screened initially with 5 minutes
homogenization (5000 rpm) and 5 minutes sonication at 20% amplitude. Size, PDI and ZP for
these formulations are provided in Table 4.1. Blank SLNs with sizes < 200 nm were obtained with
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Tween 80 (113.4 ± 9.03 nm) and Poloxamer 188 (177.2 ± 3.99). However, SLNs prepared using
Tween 80 were aggregated with particle size increasing up to 6.79 ± 3.88 µm. Therefore,
Poloxamer 188 was chosen as the stabilizer for preparation of Ag-FSE loaded SLNs.
Table 4.1: Effect of surfactants (1% w/v) on size, PDI, and ZP of blank SLNs (5 minutes
homogenization and 5 minutes sonication) Data are represented as mean ± SD
(n=3)

S.no

Surfactant

Size (nm)

PDI

ZP (mV)

1

SHS 15

356.4 ± 53.88

0.586 ± 0.12

-12.7 ± 2.64

2

RH 40

352.9 ± 158.40

0.489 ± 0.23

-17.0 ± 4.00

3

Tween 80

113.4 ± 09.03

0.401 ± 0.09

-18.3 ± 5.71

4

Poloxamer 188

177.2 ± 03.99

0.145 ± 0.04

-16.9 ± 1.38

Effect of surfactant concentration on particle size, PDI and ZP
Based on initial experiments, Poloxamer 188 was chosen as the stabilizer for preparation
of SLNs. Poloxamer 188 is a di-functional triblock copolymer surfactant with amphiphilic
properties and soluble in water and organic solvents. It is composed of a hydrophobic block
sandwiched between two hydrophilic polymer blocks. This unique structure of the surfactant helps
in coating the hydrophobic nanoparticles effectively and stabilize the system by inducing stealth
properties. Moreover, Poloxamer 188 has the ability to integrate into the membranes of the cells
and affect various cellular functions (Pradhan, Singh, and Singh 2015; X. Chen et al. 2013; Pandya
et al. 2018). Due to these properties, Poloxamer 188 has been used as a stabilizer for SLN
formulations in various reports (W. Zhang et al. 2008; Müller, Mäder, and Gohla 2000; AlloteyBabington et al. 2018; Y. Zhang et al. 2010). Increase in the concentration of Poloxamer 188 did
not have any significant effect on the particle size of blank SLNs (Figure 4.1). Therefore, 1%
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Poloxamer 188 was considered as the optimum concentration for the formulation of Ag-FSE SLNs
to limit any cytotoxicity associated with the use of surfactants (Kalhapure et al. 2014).
300
194.6 ± 52.83

1% Poloxamer

Size (nm)

2% Poloxamer

200

177.2 ± 3.99

174.5 ± 2.56

177.8 ± 12.72

3% Poloxamer
4% Poloxamer

100

0
Concentration of Poloxamer

Figure 4.1: Effect of Poloxamer 188 concentration on particle size of blank SLNs. Data are
represented as mean ± SD (n=3)
Effect of homogenization and sonication time on particle size, PDI and ZP
The effect of sonication and homogenization time on particle size, PDI, and ZP of blank
SLNs is provided in Table 4.2. Based on the results, 5 minutes homogenization and 10 minutes
sonication were considered as the optimum conditions for the formulation of Ag-FSE SLNs as
those conditions gave SLNs with smaller particle size and PDI.
Table 4.2: Effect of sonication and homogenization time on the particle size, PDI and ZP of
blank SLNs (1% Poloxamer 188). All the data are represented as mean ± SD (n=3).

S.no

Sonication

Homogenization

Size (nm)

PDI

ZP (mV)

time

time

1

5 min

5 min

177.2 ± 3.99

0.145 ± 0.04

-16.9 ± 1.38

2

10 min

5 min

162.5 ± 2.53

0.144 ± 0.03

-17.9 ± 1.56
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3

20 min

5 min

166.8 ± 4.64

0.163 ± 0.013

-2.11 ± 3.10

4

10 min

10 min

179.2 ± 9.29

0.153 ± 0.03

-0.28 ± 0.65

5

10 min

20 min

184.9 ± 4.39

0.159 ± 0.03

-0.2 ± 0.88

Preparation of Ag-FSE SLNs
Based on the preliminary results, Poloxamer 188 1%, 5 minutes homogenization and
10 minutes sonication were considered as the optimum conditions for the formulation of Ag-FSE
SLNs as those conditions gave SLNs with smaller particle size and PDI. The particle size, PDI and
ZP of the optimized Ag-FSE SLNs were 129.8 ± 38.5 nm, 0.114 ± 0.033 and -23.9 ± 3.62 mV,
respectively. Particle size for pure Ag-FSE dispersed in water was 1.42 ± 0.04 µm. Encapsulation
of Ag-FSE into SLNs reduced the particle size significantly (p <0.05). Mean particle size and ZP
distribution curve are represented by Figure 4.2 and Figure 4.3, respectively. These curves
represent the monodisperse nature of the formulation.

Figure 4.2: Size distribution curve of Ag-FSE SLNs

Figure 4.3: ZP distribution curve of Ag-FSE SLNs
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Determination of EE% and DL%
Ag-FSE SLNs exhibited high EE% and DL%. EE% and DL% for Ag-FSE SLNs were
93.49 ± 0.391 and 9.35 ± 0.039, respectively. High encapsulation of Ag-FSE in the SLNs can be
attributed to the drug-enriched core model of encapsulation. Drug distribution model in the SLNs
can be explained with the differences in the melting points of drug used and lipids (Müller, Mäder,
and Gohla 2000; X. Chen et al. 2013). Ag-FSE has higher melting point than GMS. When the
formed SLNs were cooled, the solid Ag-FSE formed the core of the SLN and the liquid GMS and
Poloxamer 188 were adsorbed on the surface of the core. Therefore, the Ag-FSE incorporation
model was the core-shell model, drug enriched core. Similar type of encapsulation model has been
reported for astragaloside loaded SLNs (X. Chen et al. 2013; Matougui et al. 2016). The
unencapsulated Ag-FSE (~6.5%) could have formed nanocrystals during homogenization and
ultrasonication process due to the stealth effect of Poloxamer 188.
SEM
SEM images of lyophilized Ag-FSE SLNs are shown in Figure 4.4. Morphology of the
SLNs from the SEM images showed that the Ag-FSE SLNs were roughly spherical in shape with
smooth surface (Figure 4.4). Aggregation was also noted in some images and could have occurred
during lyophilization process.
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Figure 4.4: SEM images of Ag-FSE SLNs. Scale bars are (a-d) 100 nm (e-f) 1 µm
XRD analysis
Crystalline nature of drug molecules determines the important properties such as solubility,
bioavailability, rate of dissolution, and stability (Kalhapure and Akamanchi 2013). XRD studies
were used to confirm the crystalline nature of Ag-FSE, Ag-FSE SLNs and other excipients used
in the formulation of SLNs. XRD results are provided in Figure 4.5 show that Ag-FSE exhibited
crystalline nature with characteristic peaks at 6.18°, 10.28°, 18.48°, 25.92°, and 32.8°. However,
the encapsulation of Ag-FSE into SLNs resulted in disappearance of these peaks confirming loss
of crystallinity (Figure 4.5). Encapsulation of Ag-FSE into SLNs resulted in its transition from
crystalline to amorphous form. Similar findings were observed with other SLN formulations
(Kalhapure and Akamanchi 2013).
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Figure 4.5: XRD of (A) Ag-FSE, (B) GMS, (C) Poloxamer 188, and (D) Ag-FSE SLN
DSC
Melting and crystalline behavior of all the materials used in the preparation of SLNs were
evaluated by DSC. Ag-FSE showed a sharp exothermic peak at 211.69 °C (Figure 4.6A). GMS,
and Poloxamer 188 showed sharp endothermic peaks at 74.47 °C, and 57.61 °C, respectively
(Figure 4.6B and 4.6C). Absence of characteristic peak for Ag-FSE at 211.69 °C (Figure 4.6D) in
the lyophilized Ag-FSE SLN confirms that the Ag-FSE was successfully encapsulated in the SLNs
transforming into amorphous form from crystalline form. Compared to crystalline form,
amorphous form of drug is characterized with higher solubilities and dissolution resulting in
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increased bioavailability (Morissette et al. 2004). Also, a sharp endothermic peak of GMS at
74.47 °C disappeared in the Ag-FSE SLN and two new endothermic peaks were observed at lower
temperatures of 54.86 °C and 68.60 °C (Figure 4.6D). Overall, DSC results complemented the
XRD results.

Figure 4.6: DSC of (A) Ag-FSE, (B) Poloxamer 188, (C) GMS, and (D) Ag-FSE SLN
In vitro release studies
In vitro release profile of Ag-FSE SLNs and Ag-FSE is presented in Figure 4.7. Release of
Ag-FSE from the SLNs was observed to be in controlled manner with a ~94% of Ag-FSE released
in 4 to 8 h and cumulative release of 91.46% at the end of 96 h. These results suggest that
encapsulation of Ag-FSE into SLNs resulted in controlled release of the drug from lipid matrix.
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Slow and controlled release of Ag-FSE from the SLNs could be due to the drug-enriched core
model. Similar results of controlled release with SLNs was observed in other studies (Mhango et
al. 2017; Kalhapure et al. 2017; X. Chen et al. 2013). Interestingly only ~22% release was released
when Ag-FSE was dispersed in PBS. This could be due to precipitation of drug in PBS and
subsequent diminished permeability through dialysis tubing. However, no precipitation for
unentrapped Ag-FSE was observed in prepared SLNs. This could be due to formation of
nanocrystals during homogenization and ultrasonication process by the stealth effect of Poloxamer
188. This was confirmed by subjecting Ag-FSE in Poloxamer 188 solution (1% w/v) to similar
homogenization and sonication conditions as used during the preparation of SLNs. It was observed
that there was formation of nanocrystals with average size of 356.5 ± 13.94 nm. However,
sedimentation of these nanocrystals occurred within an hour. When Ag-FSE was dissolved in

Cumulative amount released (%)

DMSO, 100% release was obtained within 2 h.
150

Ag-FSE SLN
Free Ag-FSE in PBS
Free Ag-FSE in DMSO

100

50

0
0 0.5 1 2 3 4 5 6 7 8 24 48 72 96
Time (h)

Figure 4.7: In vitro release profile of Ag-FSE SLNs, Ag-FSE in PBS, and Ag-FSE in DMSO.
Data are expressed in mean ± SD (n = 3).
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Physical stability studies
Freeze dried SLNs were evaluated for stability at 4 °C and 25 °C for 60 days. Initially, two
concentrations of sucrose were evaluated to obtain particles with a minimum particle size. Results
showed minimum particle size of 136.6 ± 15.93 nm was obtained with sucrose:GMS ratio of 1:1
(Table .3). Therefore, stability studies were conducted for freeze dried samples with sucrose to
GMS concentration of 1:1 at days 1, 30 and 60.
Results showed that there was no significant difference in the particle size of SLNs at Day
1, 30 and Day 60 (p> 0.05) (Table 4.4). Also, there was no sign of aggregation of nanoparticles
during the storage period at 4 °C and 25 °C. For samples stored at RT, the particle size at Day 1,
Day 30 and Day 60 were 136.6 ± 15.93 nm, 143.8 ± 37.67 nm and 200.8 ± 27.38 nm, respectively.
For samples stored at 4 °C, the particle size at Day 1, Day 30 and Day 60 were 136.6 ± 15.93 nm,
139.0 ± 23.19 nm and 146.8 ± 19.90 nm, respectively. ZP values at different timepoints also
confirmed that the freeze-dried Ag-FSE SLNs were stable throughout the storage period.
Table 4.3: Effect of sucrose concentration on size, PDI and ZP of freeze-dried Ag-FSE SLNs.
All the data are represented as mean ± SD (n=3)
GMS to Sucrose Ratio

Size (nm)

PDI

ZP (mV)

1:0.5

201.9 ± 59.14

0.337 ± 0.06

-25.1 ± 0.72

1:1

136.6 ± 15.93

0.352 ± 0.09

-23.1 ± 2.10
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Table 4.4: Effect of storage on particle size, PDI and ZP of freeze-dried Ag-FSE SLNs for 30
and 60 days at 4 °C and 25 °C. All the data are represented as mean ± SD (n=3)
Storage
Particle size (nm)

PDI

ZP

Condition
Time

4 °C

RT

4 °C

RT

4 °C

RT

136.6 ± 15.93

136.6 ±

0.352 ±

0.352 ± 0.09

-23.1 ±

-23.1 ±

15.93

0.09

2.10

2.10

143.8 ±

0.411 ±

-30.4 ±

-32.8 ±

37.67

0.11

0.58

1.59

200.8 ±

0.374 ±

-18.4 ±

-16.5 ±

27.38

0.09

4.12

3.41

(Days)
1

30

60

139.0 ± 23.19

146.8 ± 19.90

0.422 ± 0.13

0.572 ± 0.10

In vitro antibacterial activity
Antibacterial activity of SLNs was determined using broth dilution method. Results
showed that encapsulation of Ag-FSE into SLNs significantly increased the antibacterial activity
against P. aeruginosa and S. aureus. However, against E. coli, the antibacterial efficacy was
similar for Ag-FSE and Ag-FSE SLNs. These results were consistent with other studies where
encapsulation of antibiotics into SLNs enhanced the antibacterial activity. Enhancement in
antibacterial activity can be attributed to multiple simultaneous mechanisms of actions of Ag-FSE
loaded SLNs such as: i) transformation of Ag-FSE from crystalline to amorphous form; ii)
enhanced drug diffusion onto bacterial cell wall as well as better interaction with the bacterial
surface causing nanoparticle penetration into the cell due to lipidic shell of SLNs (Pignatello et al.
2018); iii) high binding avidity of silver for negatively charged side groups dispersed throughout
the microbial cells (Kalhapure et al. 2015) and iv) capacity of silver to attack numerous sites in the
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bacterial cell (Kalhapure et al. 2015; Suleman et al. 2015). No antibacterial activity was observed
for blank SLNs and 10% DMSO. Compared to Ag-FSE, Ag-FSE SLNs had 4-fold and 2-fold
enhancement in antibacterial activity against S. aureus (MIC: 15.625 µg/mL vs. 62.5 µg/mL) and
P. aeruginosa (MIC: 15.625 µg/mL vs. 31.25 µg/mL), respectively (Table 4.5).
Results from this study are consistent with our previous study of Ag-FSE nanocrystals with
few interesting findings (Table 4.6). Against S. aureus and E. coli, nanocrystals of Ag-FSE had
better activity compared to Ag-FSE and Ag-FSE SLNs. Better activity with Ag-FSE nanocrystals
against S. aureus could be due to: i) sodium dodecyl sulphate which was used as a stabilizer in
nanocrystal formulation and ii) nanocrystals are unencapsulated nano form of a drug which would
have made whole drug available immediately for exerting activity. Against S. aureus, Ag-FSE
SLNs had better activity compared to Ag-FSE. This confirms that nanonization of Ag-FSE resulted
in enhanced anti-bacterial activity compared to Ag-FSE.
Table 4.5: MIC values of antibacterial activities of Ag-FSE, 10% DMSO, Blank SLNs and AgFSE SLNs (n = 3).
MIC (µg/mL)
Formulation

E. coli

S. aureus

P. aeruginosa

(ATCC25922)

(ATCC25923)

(ATCC27853)

10% DMSO

NA

NA

NA

Blank SLNs

NA

NA

NA

Ag-FSE SLNs

125

15.625

15.625

Ag-FSE in 10% DMSO

125

62.5

31.25

NA = No activity
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Table 4.6: Comparison of antibacterial activities of Ag-FSE nanosuspension and Ag-FSE SLNs
against E. coli, S. aureus and P. aeruginosa

Enhancement of antibacterial activity compared to Ag-FSE
Formulation

E. coli

S. aureus

P. aeruginosa

(ATCC25922)

(ATCC25923)

(ATCC27853)

Ag-FSE Nanosuspension

2-fold

8-fold

No difference

Ag-FSE SLN

No difference

4-fold

2-fold

Conclusions
Encapsulation of antibiotics into SLNs can significantly improve antibacterial bacterial
activity and can sustain the drug release. In this study, Ag-FSE, a new antibacterial agent with
poor solubility was successfully encapsulated into SLNs to enhance its antibacterial activity. AgFSE was encapsulated into SLNs with %EE of ~93%. In vitro release studies confirmed that
encapsulation of Ag-FSE into SLNs resulted in sustained release of Ag-FSE over 96 h. Results
also confirmed that there was a 2-fold and 4-fold enhancement of activity against P. aeruginosa
and S. aureus respectively. Stability studies confirmed that there was no sign of aggregation of
nanoparticles during the storage period at 4 °C and 25 °C. In conclusion, formulation of Ag-FSE
SLNs significantly enhanced the antibacterial efficacy with sustained release profile. Ag-FSE
SLNs can be considered as a promising topical antibacterial agent against bacterial infections.
However, the findings in this study are preliminary and should be further confirmed with
preclinical studies before clinical applications.
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Future studies
In this dissertation project, I have successfully prepared and characterized solid lipid
nanoparticles for enhancing the antibacterial activity of furosemide silver complex using several
in vitro techniques. Future studies for extension of this project includes: (1) Determination of
in vivo antibacterial efficacy of Ag-FSE SLNs in MRSA infected mice model and (2) To evaluate
the in vivo pharmacokinetics and tissue distribution of Ag-FSE loaded SLNs.
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Chapter 5: Impact on Public Health
The primary aim of developing new formulations/drug delivery systems is to improve the
therapeutic performance, achieve sustained efficacy and better patient compliance. In this
dissertation, I have developed three novel formulations for drugs (clotrimazole, lutein and
furosemide silver complex) with low aqueous solubility, affecting the efficacy/bioavailability.
Globally, fungal infections affect around one billion people and are the primary cause of
death in one million patients annually. These infections are usually associated as secondary
infections in immunocompromised patients such as AIDs and tuberculosis. Clotrimazole, an
antifungal agent is widely used to treat these infections. It is the first oral azole approved for fungal
infections; however, it is not used orally sue to systemic toxicity. It is currently available as topical
formulations such as cream, solution and lotion, however, the bioavailability is very low (5-10%)
due to poor solubility. In the first study, I loaded clotrimazole into novel lipid-based drug delivery
system (ufosomes) prepared using cholesterol and sodium oleate. There was a significant increase
in the topical bioavailability of clotrimazole. Moreover, cholesterol and sodium oleate are
inexpensive and easy to procure. Overall, clotrimazole loaded ufosomes could be advantageous in
treating fungal infections effectively, help in increasing patient compliance due to reduced
frequency in application.
In the second study I have formulated lutein loaded folate decorated nano-formulation to
enhance the uptake of a neuroprotective agent, lutein. Neonatal HIE affects approximately 0.1%
to 0.3% of live births in developed nations and 2.6% in under-developed nations and is responsible
for 23% of neonatal deaths. Survivors of neonatal HIE develop severe neurological abnormalities
such as cerebral palsy, seizures, and blindness. Currently therapeutic hypothermia is the only gold
standard treatment; however, it is successful only in 50-60% of the cases. Lutein, a neuroprotective
agent has shown to be effective in reducing inflammatory mediators, brain injury and HIF-α.
However, poor solubility limits its bioavailability in neonates and mother’s milk. Supplementation
of lutein with the prepared nano-formulation to the mother and neonate is expected to increase
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lutein levels in the brain and reduce the hypoxic ischemic shock. This novel formulation could be
valuable in reducing the deaths associated with HIE.
There is a significant rise in the incidence of antibiotic resistant infections. According to
the CDC, mortality associated with these infections is around 23,000 patients annually and causes
an annual economic burden of 20 billion dollars in direct costs and 35 billion dollars in indirect
costs in the US alone. The CDC has recommended the development of new antibiotics to combat
these infections. Silver complexes have been used as a prophylactic and treatment for bacterial
infections associated with skin burns. Furosemide-silver is a novel synthetic agent effective against
wide range of bacterial infections however, poor solubility limits its activity. I have developed a
novel solid lipid nanoparticle formulation for furosemide silver complex and enhanced its activity
and provided a sustained release profile. This formulation could potentially be used as a novel
topical antibacterial agent for treating infections associated with burns and reduce the systemic
effects of silver toxicity.
Thus, the new formulations developed have advantages such as dose flexibility, easier
administration, and better acceptance by all patient population.
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